Novel compounds for the inhibition of Janus kinase 1
1H-imidazo[4,5-b]pyridin-2(3H)-ones are developed as selective JAK1 inhibitors to address the non-selectivity of current JAK kinase inhibitors, offering a safer and more targeted treatment for immune-mediated diseases and cancers by minimizing JAK2 inhibition-related side effects.
Patent Information
- Application Number
- JP2021570725
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-05-28
- Filing Date
- 2020-05-26
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2040-05-26
AI Technical Summary
Current JAK kinase inhibitors are non-selective, leading to adverse effects due to the inhibition of multiple JAK isoforms, particularly JAK2, necessitating the development of isoform-specific inhibitors to minimize these side effects while maintaining efficacy in treating immune-mediated diseases and cancers.
Development of 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their pharmaceutically acceptable salts as selective inhibitors of JAK1, which target specific signaling pathways involved in oncology, inflammation, and autoimmune diseases.
The selective JAK1 inhibitors effectively intervene in relevant signaling pathways with reduced adverse effects, providing a safer and more targeted therapeutic approach.
Smart Images

Figure 0007592029000313 
Figure 0007592029000314 
Figure 0007592029000001
Abstract
Description
[Technical field]
[0001] The present invention relates to inhibitors of Janus kinase 1 (JAK1), methods for the synthesis of the compounds of the invention, compositions comprising the compounds and uses of the compounds for the inhibition of JAK1. [Background technology]
[0002] Cytokines are the main drivers of several biological pathways and anti-cytokine therapy is indicated if there is any dysregulation in the pathway. Signaling pathways for type I and type II cytokine receptors, a family of receptors utilized by over 50 cytokines, interleukins, interferons, colony stimulating factors, and hormones. As with other receptor superfamilies, type I and type II cytokine receptors are implicated in these intracellular signaling modes: all of them utilize JAK. Janus kinases (JAKs) are intracellular tyrosine kinases linked to many cytokine receptors in the intracellular domain. There are four JAK isoforms: JAK1, JAK2, JAK3, and TYK2. JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2) bind directly to the intracellular domain of type I / II cytokine receptors but not to other classes of cytokine receptors. Different cytokine receptor families utilize specific JAK isoforms for signaling. Phosphorylation of JAKs upon binding of a cytokine to its cognate receptor leads to phosphorylation of other intracellular molecules, which ultimately results in gene transcription. JAK-dependent cytokines are major contributors to immunopathology, and blocking such cytokines with biologics may be beneficial in immune-mediated diseases and cancer, as well as several other major diseases and disorders.
[0003] There are several JAK kinase inhibitors. These block multiple JAKs and therefore inhibit a wide variety of cytokine actions, and several panJAK inhibitors are continuing to be developed. JAK isoforms have different functions, and therefore there is a need in the art for isoform-specific inhibitors that can reduce the undesired effects from the administration of systemic JAK inhibitors. JAK1 plays a major role in type I and II interferon signaling, and elicits signals from interleukin 2, interleukin 4, gp130 and class II receptor families. Thus, small molecule inhibition of JAK1 can intervene in signaling pathways that are involved in oncology, inflammation and autoimmune diseases. However, to minimize adverse effects, especially those resulting from JAK2 inhibition, the generation of selective inhibitors would in principle maintain efficacy and improve safety. Summary of the Invention
[0004] It is an object of the present invention to provide compounds, methods for the preparation of the inhibitors, compositions containing the compounds and the utility of the compounds as selective JAK1 inhibitors. The present invention discloses 1H-imidazo[4,5-b]pyridin-2(3H)-ones of formula I, their pharma- ceutically acceptable salts and isomers as selective inhibitors of JAK1. [ka] [In the formula, A is a 5- or 6-membered carbocyclic or heterocyclic ring containing 1 to 3 heteroatoms selected from the group including O, N, S, which may be substituted with CH3, F or Cl; B is H or alkoxy or a 3-8 membered heterocyclic ring containing 1-3 heteroatoms selected from the group consisting of O, -CO-, an optionally substituted 3-8 carbon ring, O, N, and S; X is independently H, (CH2)n, -CO-, OCO, COO; CO(CH2)n, (NH2)n; (CH2)n(NH2)n; (CH2)n(NH2)nCN; CONH; CONR1R2, CO(NH2)n; (CH2)nCO(NH2)n, CO(NH2)n(CH2)CF3, SO2(CH2)n, NH(CH2)nCN, an unsubstituted or substituted 3-8 membered carbocylic ring, or a heterocyclic ring containing 1-3 heteroatoms selected from the group including O, N, S, and SO2, and the substituents on the carbocyclic ring or heterocyclic ring may be selected from halogen, alkoxy, CHMe, -CH(CF3), -C(CF3)(OH), C(CF3)(OMe), -CH(CN), CHOH, CH(R5); Y may be absent or may be H, R1, R2, halo, C1-C6 alkyl, C1-C6 alkoxyCN, -CO-, COR1, (CH2)n, -(CH2)nCN-, CH2CF3, COOH, OR1, NR1R2, -COOR1, -CON(R1)2, -SO2(CH2)n, -SON(R1)2, -OCOR1, CONHCH(CH3)-CF3, CH2CN, CH2SO2CH3-NR1COR1, -CONH, CONR1R2, -CO(NH2)n(CH2)nSO2; -CONH(CH2)nOH, CONH(CH2)nSO2R1R2, -CONH-(CH2)nCF3, -CONH(CH2)nCF3, -NHCONH(CH2)nCF3, N HCONHR1, -NHCOR1R2, NR1CONR1R2, (NH2)n, -NH2CH2, NH2CH2CF3, -CH(CF3)-(CH)n-CO-N-R1R2, CH(CF3)-(CH)n-SO2, (CH)n;CH(OH)(CF3)(Heretocycle)R1, an optionally substituted 3-8 membered carbocyclic ring, or a 3-8 membered saturated, mono, fused or bridged heterocyclic ring containing 1-3 heteroatoms or SO2 selected from the group including O, N, S, an optionally substituted 3-8 membered heterocyclic ring containing 1-3 heteroatoms or SO2 selected from the group including O, N, S, wherein the substitutions are independently selected from the ring; C 1-6 Alkaril, ArC 1-6R1 and R2 may be at any position of the alkyl; R1 and R2 are independently selected from the group consisting of H, halo, CN, CF3, hydroxyl, amino, SO2, SO2, C1-C6 alkyl, SO2-C3-C8-cycloalkyl, CH2CN, CH2CF3, unsubstituted or substituted C1-C6 straight chain or branched alkyl, the substituents being halo, OH, CN, C1-C6 alkoxy, optionally substituted NH2, C1-C6 alkylsulfonyl, optionally substituted CONH2, unsubstituted or substituted C3-C8 carbocyclyl or a 3-8 membered heterocyclic ring having 1-3 heteroatoms selected from O, N and S, SO2, C1-C6 straight chain or branched alkenyl, C1-C6 straight chain or branched alkynyl, C1-C6 alkyloxy; C1-C6 alkylamino, C1-C6 alkylca; carbonyl, C(O)-C3-C8-cycloalkyl, heteroalkyl, optionally substituted CONH2, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C3-C8 heterocycloalkyl, C3-C8 heterocycloalkenyl, carbocyclyl, aryl, and heteroaryl, -CH(CF3)-(CH)n-CO-N-R3R4, -CH(CF3)-(CH)n-SO2-NR3R4, CH(CF3)-(CH)n-NR3R4, CH(CF3)-(CH)n-SO2-CHR3R4, wherein the cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, carbocyclyl, aryl, and heteroaryl groups are optionally substituted; R3 and R4 are H, independently CH3, C3-C8 cycloalkyl; R5 is an unsubstituted or substituted 3- to 8-membered carbocyclic ring or heterocyclic ring containing 1 to 3 heteroatoms selected from the group including O, N, and S, SO2; R6 is independently H, C1-C6 straight or branched alkyl, halogen; X can be linked to Y at any atom to arrive at a chemically viable bond; n is 0 to 3.
[0005] The invention also discloses methods for preparing the compounds of the invention, compositions comprising the compounds of the invention and the utility of the compounds of the invention as selective JAK1 inhibitors. [Brief description of the drawings]
[0006] [Figure 1a] Figure 1 shows cumulative psoriasis scores and body weights of Examples 1133 and 1215 in IMQ-induced psoriasis mouse model. Figure 1a is based on psoriasis scores. Data are shown as mean ± SEM (n=8), *significantly different compared to vehicle control group. #significantly different compared to untreated control group. Two-way ANOVA followed by Bonferroni test. **P<0.01### / ***P<0.001. [Figure 1b] Figure 1b is related to body weight. Data are shown as mean ± SEM (n = 8). #Significantly different compared to untreated control. Two-way ANOVA followed by Bonferroni test. #P < 0.05. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0007] The present invention discloses 1H-imidazo[4,5-b]pyridin-2(3H)-ones of formula I, pharma- ceutically acceptable salts and isomers thereof, as selective inhibitors of JAK1. [ka] [In the formula, A is a 5- or 6-membered carbocyclic or heterocyclic ring containing 1 to 3 heteroatoms selected from the group including O, N, S, which may be substituted with CH3, F or Cl; B is H or alkoxy or a 3-8 membered heterocyclic ring containing 1-3 heteroatoms selected from the group consisting of O, -CO-, an optionally substituted 3-8 carbon ring, O, N, and S; X is independently H, (CH2)n, -CO-, OCO, COO; CO(CH2)n, (NH2)n; (CH2)n(NH2)n; (CH2)n(NH2)nCN; CONH; CONR1R2, CO(NH2)n; (CH2)nCO(NH2)n, CO(NH2)n(CH2)CF3, SO2(CH2)n, NH(CH2)nCN, an unsubstituted or substituted 3-8 membered carbocyclic ring or heterocyclic ring containing 1-3 heteroatoms selected from the group including O, N, S and SO2, and the substituents on the carbocyclic or heterocyclic ring may be selected from halogen, alkoxy, CHMe, -CH(CF3), -C(CF3)(OH), C(CF3)(OMe), -CH(CN), CHOH, CH(R5); Y may be absent or may be H, R1, R2, halo, C1-C6 alkyl, C1-C6 alkoxyCN, -CO-, COR1, (CH2)n, -(CH2)nCN-, CH2CF3, COOH, OR1, NR1R2, -COOR1, -CON(R1)2, -SO2(CH2)n, -SON(R1)2, -OCOR1, CONHCH(CH3)-CF3, CH2CN, CH2SO2CH3-NR1COR1, -CONH, CONR1R2, -CO(NH2)n(CH2)nSO2; -CONH(CH2)nOH, CONH(CH2)nSO2R1R2, -CONH-(CH2)nCF3, -CONH(CH2)nCF3, -NHCONH(CH2 )nCF3, NHCONHR1, -NHCOR1R2, NR1CONR1R2, (NH2)n, -NH2CH2, NH2CH2CF3, -CH(CF3)-(CH)n-CO-N-R1R2, CH(CF3)-(CH)n-SO2, (CH)n;CH(OH)(CF3)(heterocycle)R1, an optionally substituted 3-8 membered carbocyclic ring, or a 3-8 membered saturated, mono, fused or bridged heterocyclic ring containing 1-3 heteroatoms or SO2 selected from the group including O, N, S, an optionally substituted 3-8 membered heterocyclic ring containing 1-3 heteroatoms or SO2 selected from the group including O, N, S, the substitutions being independently selected from the ring; C 1-6 Alkaril, ArC 1-6 R1 and R2 may be at any position of the alkyl; R1 and R2 are independently selected from the group consisting of H, halo, CN, CF3, hydroxyl, amino, SO2, SO2, C1-C6 alkyl, SO2-C3-C8-cycloalkyl, CH2CN, CH2CF3, unsubstituted or substituted C1-C6 straight or branched alkyl, the substituents being halo, OH, CN, C1-C6 alkoxy, optionally substituted NH2, C1-C6 alkylsulfonyl, optionally substituted CONH2, unsubstituted or substituted C3-C8 carbocyclyl or a 3-8 membered heterocyclic ring having 1-3 heteroatoms selected from O, N and S, SO2, C1-C6 straight or branched alkenyl, C1-C6 straight or branched alkynyl, C1-C6 alkyloxy; C1-C6 alkylamino, C1-C 6 alkylcarbonyl, C(O)-C3-C8-cycloalkyl, heteroalkyl, optionally substituted CONH2, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C3-C8 heterocycloalkyl, C3-C8 heterocycloalkenyl, carbocyclyl, aryl, and heteroaryl, -CH(CF3)-(CH)n-CO-N-R3R4, -CH(CF3)-(CH)n-SO2-NR3R4, CH(CF3)-(CH)n-NR3R4, CH(CF3)-(CH)n-SO2-CHR3R4, wherein the cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, carbocyclyl, aryl, and heteroaryl groups may be optionally substituted; R3 and R4 are H, independently CH3, C3-C8 cycloalkyl; R5 is an unsubstituted or substituted 3- to 8-membered carbocyclic ring or heterocyclic ring containing 1 to 3 heteroatoms selected from the group including O, N, and S, SO2; R6 is independently H, C1-C6 straight or branched alkyl, halogen; X can be linked to Y at any atom to arrive at a chemically viable bond; n is 0 to 3.
[0008] The compounds disclosed herein and their pharma- ceutically acceptable salts can exist as single stereoisomers, racemates, and mixtures of enantiomers and diastereomers.The compounds disclosed herein can also exist as geometric isomers.All such single stereoisomers, racemates, and mixtures thereof, and geometric isomers are intended to be within the scope of the compounds disclosed herein.
[0009] Exemplary compounds of formula I of the present invention are illustrated in Table 1 herein below.
[0010] [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12]
Table 1-13
Table 1-14
Table 1-15
Table 1-16
Table 1-17
Table 1-18
Table 1-19
Table 1-20
Table 1-21
Table 1-22
Table 1-23
Table 1-24
Table 1-25
Table 1-26
Table 1-27
Table 1-28
Table 1-29
Table 1-30
Table 1-31
Table 1-32
Table 1-33
Table 1-34
Table 1-35
Table 1-36
Table 1-37
Table 1-38
Table 1-39
Table 1-40
Table 1-41
Table 1-42
Table 1-43
Table 1-44
Table 1-45
Table 1-46
[0011] Compounds of the invention include: 1001. N-(2,2,2-trifluoroethyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)benzamide; 1002. 1-(1,1,1-trifluoropropan-2-yl)-3-(4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)phenyl)urea; 1003. 1-(2,2,2-trifluoroethyl)-3-(4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)phenyl)urea; 1004. 1-(2,2,2-trifluoroethyl)-3-(5-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)pyrimidin-2-yl)urea; 1005. 1-(2,2,2-trifluoroethyl)-3-(5-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)pyridin-2-yl)urea; 1006. 1-(5-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yl)pyrazin-2-yl)-3-(2,2,2-trifluoroethyl)urea; 1007. N-(4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3,3-dimethylazetidine-1-carboxamide; 1008. N-(4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)phenyl)morpholine-4-carboxamide; 1009. 1-(4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(pyridin-4-yl)urea; 1010. 1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(2,2,2-trifluoroethyl)urea; 1011. N-(2,2,2-trifluoroethyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)piperazine-1-carboxamide; 1012. N-(cyanomethyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)piperazine-1-carboxamide; 1013. 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-N-(2-(methylsulfonyl)ethyl)piperazine-1-carboxamide; 1014. 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-N-(pyridin-4-yl)piperazine-1-carboxamide; 1015. N-(2-fluoropyridin-4-yl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)piperazine-1-carboxamide; 1016. N-(1-(methylsulfonyl)piperidin-4-yl)-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yl)piperazine-1-carboxamide; 1017. N-(cyclopentylmethyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)piperazine-1-carboxamide; 1018. 7-(4-(1,1-dioxidothiomorpholine-4-carbonyl)piperazin-1-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one; 1019. 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-N-(2-methoxypyridin-4-yl)piperazine-1-carboxamide; 1020. N-(1,1-dioxidetetrahydro-2H-thiopyran-4-yl)-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yl)piperazine-1-carboxamide; 1021. N-(1,1,1-trifluoropropan-2-yl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)piperazine-1-carboxamide; 1022. N-(2,2,2-trifluoroethyl)-4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)piperazine-1-carboxamide; 1023. 7-(4-(3,3-dimethylazetidine-1-carbonyl)piperazin-1-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one; 1024. 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-N-(2-methyl-4-(methylsulfonyl)phenyl)piperazine-1-carboxamide; 1025. N-(2,2,2-trifluoroethyl)-2-(4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)acetamide; 1026. N-(2,2,2-trifluoroethyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1027. N-(cyanomethyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1028. N-(2,2,2-trifluoroethyl)-3-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrrole-1-carboxamide; 1029. N-(2,2,2-trifluoroethyl)-4-(2,3-dihydro-1-methyl-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1030. N-(1,1,1-trifluoropropan-2-yl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1031. 7-(1-(4,4,4-trifluorobutanoyl)-1H-pyrazol-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one; 1032. N-(1-cyanocyclopropyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1033. N-(2-cyanopropan-2-yl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1034. N-(Cyclopentylmethyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1035.N-(cyanomethyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide hydrochloride; 1036. N-(2,2,2-trifluoroethyl)-4-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)-1H-pyrazole-1-carboxamide; 1037. 7-(1-(3,3-Dimethylazetidine-1-carbonyl)-1H-pyrazol-4-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one; 1038. N-(cyano(cyclopentyl)methyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1039. N-(2-cyano-1-cyclopentylethyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1040. N-(2-cyanobutan-2-yl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1041. N-(1-cyclopentyl-2,2,2-trifluoroethyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1042. 4-(1-Ethyl-2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-N-(2,2,2-trifluoroethyl)-1H-pyrazole-1-carboxamide; 1043. N-(cyano(cyclopropyl)methyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1044. N-(1-cyano-2-methylpropyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1045. N-(2,2,2-trifluoroethyl)-4-(2,3-dihydro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazole-1-carboxamide; 1046. N-(1-cyanopropan-2-yl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1047. N-((S)-1-Cyano-2-methylpropyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1048. 1-(4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carbonyl)azetidine-3-carbonitrile; 1049. N-((R)-1-cyano-2-methylpropyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1050. N-(3-cyano-1,1,1-trifluoropropan-2-yl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1051. N-(2-cyano-1-cyclopropylethyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1052. N-(1-cyanopropan-2-yl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1053. N-(1-cyanopropan-2-yl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1054. N-((R)-Cyano(cyclopropyl)methyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1055. 1-(4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carbonyl)pyrrolidine-3-carbonitrile; 1056. N-(3-cyanocyclobutyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1057. 2-(1-(4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carbonyl)pyrrolidin-3-yl)acetonitrile; 1058. N-(1-(3-cyanoazetidin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1059. N-(2-(3-cyanoazetidin-1-yl)-2-oxoethyl)-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1060. N-(2-(3-cyanoazetidin-1-yl)-2-oxoethyl)-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1061. 3-(1-(4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carbonyl)pyrrolidin-3-yl)propanenitrile; 1062. N-(2-cyano-1-(tetrahydro-2H-pyran-4-yl)ethyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1063. N-(cyano(phenyl)methyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1064. N-(2,2,2-trifluoroethyl)-4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1065. N-(2-cyano-1-(tetrahydro-2H-pyran-4-yl)ethyl)-4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1066. N-(2-cyanocyclohexyl)-4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1067. 1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carbonyl)piperidine-4-carbonitrile; 1068. N-(1-(3-cyanoazetidin-1-yl)propan-2-yl)-4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1069. N-(1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carbonyl)pyrrolidin-3-yl)propane-1-sulfonamide; 1070. N-(cyano(phenyl)methyl)-4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1071. N-(1-cyano-3-methoxypropyl)-4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1072. N-(1-cyano-3-(methylsulfonyl)propyl)-4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1073. N-((S)-1-Cyano-2-methylpropyl)-4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1074. 1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carbonyl)-4-methylpyrrolidine-3-carbonitrile; 1075. 2-(2-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)oxazol-4-yl)acetonitrile; 1076. 2-(2-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)thiazol-4-yl)acetonitrile; 1077. 7-(1-((oxazol-5-yl)methyl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1078. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)acetonitrile; 1079. 6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridine-3-carbonitrile; 1080. 7-(1-(5-((methylsulfonyl)methyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1081. 7-(1-(5-((oxetan-3-yl)methyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1082.2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)acetonitrile hydrochloride; 1083. (6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)methanol; 1084. 7-(1-(5-(2,2,2-trifluoroethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1085. 7-(1-(5-(morpholinomethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1086. 4-((6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)methyl)thiomorpholine 1,1-dioxide; 1087. 1-((6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)methyl)azetidine-3-carbonitrile; 1088. 6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)-N-(cyanomethyl)pyridine-3-carboxamide; 1089. N-((6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)methyl)methanesulfonamide; 1090. N-((6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)methyl)methanesulfonamide; 1091. N-((6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)methyl)-2-cyanoacetamide; 1092. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-N-(2,2,2-trifluoroethyl)acetamide; 1093. 2-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)-N-(cyanomethyl)pyrimidine-5-carboxamide; 1094. N-(2,2,2-trifluoroethyl)-4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1095. 4-(2-ethoxy-3H-imidazo[4,5-b]pyridin-7-yl)-N-(2,2,2-trifluoroethyl)-1H-pyrazole-1-carboxamide; 1096. 4-(2-Cyclopropyl-3H-imidazo[4,5-b]pyridin-7-yl)-N-(2,2,2-trifluoroethyl)-1H-pyrazole-1-carboxamide; 1097. 3-(4-(2-(4-chloro-3-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)-tetrahydro-2H-pyran-4-carbonitrile; 1098. 4-(2-(1-acetylpiperidin-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)-N-(2,2,2-trifluoroethyl)-1H-pyrazole-1-carboxamide; 1099. 2-(4-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)phenyl)acetonitrile; 1100. 2-(4-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)phenyl)-2-cyclopropylacetonitrile; 1101. 2-(4-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)phenyl)-2-morpholinoacetonitrile; 1102. N-(4-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)phenyl)-2-cyanoacetamide; 1103. 2-(4-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)-3-fluorophenyl)acetonitrile; 1104. 2-(4-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)-2-fluorophenyl)acetonitrile; 1105. 2-(4-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)-2-methoxyphenyl)acetonitrile; 1106. 2-(3-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)phenyl)acetonitrile; 1107. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)propanenitrile; 1108. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)propanamide; 1109. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)cyclopropanecarbonitrile; 1110. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-cyclopropylacetonitrile; 1111. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(3,3-difluoroazetidin-1-yl)acetonitrile; 1112. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-morpholinoacetonitrile; 1113. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(1,1-dioxidethiomorpholino)acetonitrile; 1114. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(1-(methylsulfonyl)azetidin-3-yl)acetonitrile; 1115. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(1-(methylsulfonyl)azetidin-3-yl)acetonitrile; 1116. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4-(methylsulfonyl)butanenitrile; 1117. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-2-yl)acetonitrile; 1118. 2-(2-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-4-yl)acetonitrile; 1119. 7-(1-(5-(2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1120. 7-(1-(5-(1-chloro-2,2,2-trifluoroethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1121. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-N,N-dimethylethanamine; 1122. 7-(1-(5-(1,1,1-trifluorobutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1123. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutanenitrile; 1124. 7-(1-(5-(2,2,2-trifluoro-1-isopropoxyethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1125. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1,1,1-trifluoropropan-2-ol; 1126. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-cyclopropyl-2,2,2-trifluoroethanol; 1127. 7-(1-(5-(1-cyclopropyl-2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1128. 7-(1-(5-(1,1,1,2-tetrafluoropropan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1129. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1,1,1-trifluoro-3-methylbutan-2-ol; 1130. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-cyclohexyl-2,2,2-trifluoroethanol; 1131. 1-(4-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidin-1-yl)ethanone; 1132. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-cyclopentyl-2,2,2-trifluoroethanol; 1133. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylpiperidin-4-yl)ethanol; 1134. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(tetrahydro-2H-pyran-4-yl)ethanol; 1135. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(piperidin-4-yl)ethan-1-ol 1135. 7-(1-(5-(2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1136. 7-(1-(5-(2,2,2-trifluoro-1-morpholinoethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1137. 7-(1-(5-(1,1,1-trifluoro-3-(methylsulfonyl)propan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1138. 7-(1-(5-(4-(cyclopropylsulfonyl)-1,1,1-trifluorobutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1139. 7-(1-(5-(1-((methylsulfonyl)methoxy)-2,2,2-trifluoroethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1140. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutane-1-sulfonamide; 1141. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutane-1-sulfonamide; 1142. N-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)methanesulfonamide; 1143. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N,N-dimethylbutanamide; 1144. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutanamide; 1145. 1-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethyl)-3-cyclopropylurea; 1146. 7-(1-(5-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one; 1147. 4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-5,5,5-trifluoro-N-methylpentanamide; 1148. N-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)cyclopropanecarboxamide; 1149. 4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-N-cyclopropyl-5,5,5-trifluoropentanamide; 1150. N-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)cyclopentanecarboxamide; 1151. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutan-1-amine; 1152. N-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)cyclopropanamine; 1153. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutan-1-ol; 1154. 7-(1-(5-(1,1,1-trifluoro-4-methoxybutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1155. 4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-5,5,5-trifluoropentanenitrile; 1156. 2-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)acetonitrile; 1157. 7-(1-(5-(1-(methylsulfonyl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1158. (6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)(cyclopropyl)methanol; 1159. 7-(1-(5-(3-(methylsulfonyl)-1-(oxetan-3-yl)propyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1160. 7-(1-(5-(1-methoxy-3-(methylsulfonyl)propyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1161. 7-(1-(5-(1-fluoro-3-(methylsulfonyl)propyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1162. 7-(1-(5-(4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1163. (6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)(1-(methylsulfonyl)piperidin-4-yl)methanol; 1164. (6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)(1-methylpiperidin-4-yl)methanol; 1165. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-N-(2,2,2-trifluoroethyl)-2-hydroxyacetamide; 1166. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-cyclopropyl-N-(2,2,2-trifluoroethyl)acetamide; 1167. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-cyano-N-(2,2,2-trifluoroethyl)acetamide; 1168. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethanol; 1169. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-2-yl)-2,2,2-trifluoroethanol; 1170. 7-(1-(6-(2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1171. 1-(2-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-4-yl)-2,2,2-trifluoroethanol; 1172. 1-(5-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-2-yl)-2,2,2-trifluoroethanol; 1173. 7-(1-(5-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1174. 7-(1-(6-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1175. 7-(1-(4-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1176. 1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carbonyl)pyrrolidine-3-carbonitrile 1177. 1-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethyl)-3-cyclopropylurea 1178. 1-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)-3-cyclopropylurea 1179. 3-Cyclopentyl-3-(4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)propanenitrile 1180. 3-Cyclopentyl-3-(4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)propanenitrile 1181. 7-(1-(5-((S)-1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 1182. 7-(1-(5-((R)-1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 1183. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1,1,1-trifluoropropan-2-ol 1184. 7-(1-(5-((R)-2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 1185. 7-(1-(5-((S)-2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 1186. 7-(1-(5-(1,1,1-trifluoro-4-(isopropylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 1187.1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-(methylsulfonyl)1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethaneamine 1188. 7-(1-(5-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-(cyclopropylaminosulfonyl)1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 1189. 7-(1-(5-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one 1190. 7-(1-(4-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)phenyl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 1191. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(trifluoromethyl)propan-1-ol 1192. N-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethyl)-2-cyanoacetamide 1193. 4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-5,5,5-trifluoro-2-methylpentan-2-ol 1194. 7-(1-(5-(3,3,3-trifluoro-2-((methylsulfonyl)methyl)propyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 1195. N-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)-N-methylcyclopropanamine 1196. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-2,2-dimethylbutan-1-ol 1197. N-(2-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)ethyl)cyclopropanamine 1198. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutan-1-amine 1199. N-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)cyclohexanamine 1200. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutan-1-amine 1201. 7-(1-(5-(1,1,1-trifluoro-4-morpholinobutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 1202. 1-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)azetidine-3-carbonitrile 1203. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-isopropylbutan-1-amine 1204. 7-(1-(5-(4-(cyclopropylmethylsulfonyl)-1,1,1-trifluorobutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 1205. 7-(1-(5-(3-(cyclopropylmethylsulfonyl)-1,1,1-trifluoropropan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 1206. 7-(1-(5-(1,1,1-trifluoro-3-morpholinopropan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 1207. (S)-3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-isopropylbutan-1-amine 1208. (R)-3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-isopropylbutan-1-amine 1209.2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-(methylsulfonyl)1H-pyrazol-1-yl)pyridin-3-yl)-3,3,3-trifluoropropan-1-amine 1210. 4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-5,5,5-trifluoro-N-isopropylpentanamide 1211. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N,N-diisopropylbutan-1-amine 1212. N-(2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-3,3,3-trifluoropropyl)cyclopropanamine 1213. (R)-3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutanamide 1214. (S)-3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutanamide 1215. (S)-4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-5,5,5-trifluoro-N-isopropylpentanamide 1216. 7-(1-(5-((S)-4-(cyclopropylsulfonyl)-1,1,1-trifluorobutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 1217. (S)-3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutan-1-amine, TFA salt 1218. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-3,3,3-trifluoro-N-isopropylpropan-1-amine 1219. 7-(1-(5-(1,1,1-trifluoro-4-(4-methylpiperazin-1-yl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 1220. (4-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidin-1-yl)(cyclopropyl)methanone 1221. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-(1-ethylpiperidin-4-yl)-2,2,2-trifluoroethanol 1222. 7-(1-(5-(1,1,1-trifluoro-3-(4-methylpiperazin-1-yl)propan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 1223. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1,1,1-trifluoro-4-(methylsulfonyl)butan-2-ol 1224. 5-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-6,6,6-trifluorohexan-2-amine, TFA salt 1225. (R)-1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-isopropylpyrrolidin-3-yl)ethanol 1226. (S)-1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-isopropylpyrrolidin-3-yl)ethanol 1227. 4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-5,5,5-trifluoro-4-hydroxypentanenitrile 1228. 2-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)-N-methylethanamine 1229. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1,1,1-trifluoro-3-morpholinopropan-2-ol 1230. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1,1,1-trifluoro-4-morpholinobutan-2-ol 1231. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylazetidin-3-yl)ethanol 1232. (R)-1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-(1-ethylpyrrolidin-3-yl)-2,2,2-trifluoroethanol 1233. (S)-1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-(1-ethylpyrrolidin-3-yl)-2,2,2-trifluoroethanol 1234. (S)-1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylpyrrolidin-3-yl)ethanol 1235. (R)-1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylpyrrolidin-3-yl)ethanol 1236. 1-(3-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)azetidin-1-yl)ethanone 1237. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-isopropylazetidin-3-yl)ethanol 1238. 4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-5,5,5-trifluoro-4-hydroxy-N-isopropylpentanamide 1239. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-(1-ethylazetidin-3-yl)-2,2,2-trifluoroethanol 1240. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-isopropylpiperidin-4-yl)ethanol 1241. N-(2-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)ethyl)propan-2-amine, TFA salt 1242. (R)-1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-(oxetan-3-yl)pyrrolidin-3-yl)ethanol 1243. (S)-1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-(oxetan-3-yl)pyrrolidin-3-yl)ethanol 1244. 7-(1-(5-(2,2,2-trifluoro-1-methoxy-1-(1-methylpiperidin-4-yl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 1245. 3-(3-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)azetidin-1-yl)-3-oxopropanenitrile 1246. 3-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)-N-methylazetidine-1-carboxamide 1247. N-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)isobutyramide 1248. N-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)-2-cyanoacetamide 1249. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-1-morpholinobutan-1-one 1250. 1-(4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-5,5,5-trifluoropentanoyl)azetidine-3-carbonitrile 1251. (S)-1-(4-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoro-1-(1-isopropylpyrrolidin-3-yl)ethanol 1252. (R)-1-(4-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoro-1-(1-isopropylpyrrolidin-3-yl)ethanol
[0012] The present invention discloses novel compounds of 1H-imidazo[4,5-b]pyridin-2(3H)-ones of formula II, their pharma- ceutically acceptable salts and isomers. [ka] [In the formula, B is H, X is independently H, (CH2)n, -CO-, OCO, COO; CO(CH2)n, (NH2)n; (CH2)n(NH2)n; (CH2)n(NH2)nCN; CONH; CONR1R2, CO(NH2)n; (CH2)nCO(NH2)n, CO(NH2)n(CH2)CF3, SO2(CH2)n, NH(CH2)nCN, an unsubstituted or substituted 3-8 membered carbocyclic ring, or a heterocyclic ring containing 1-3 heteroatoms selected from the group including O, N, S, and SO2, Substituents on the ring or heterocyclic ring are halogen, alkoxy, CHMe, -CH(CF3), -C(CF3)(OH), C(CF3)(OMe), -CH(CN), CHOH, CH(R5), H, R1, R2, halo, C1-C6 alkyl, C1-C6 alkoxyCN, -CO-, COR1, (CH2)n, -(CH2)nCN-, CH2CF3, COOH, OR1, NR1R2, -COOR1, -CON(R1)2, -SO2(CH2)n, -SON(R1)2, -OCOR1, CONH CH(CH3)-CF3, CH2CN, CH2SO2CH3-NR1COR1, -CONH, CONR1R2, -CO(NH2)n(CH2)nSO2;-CONH(CH2)nOH, CONH(CH2)nSO2R1R2, -CONH-(C H2)nCF3, -CONH(CH2)nCF3, -NHCONH(CH2)nCF3, NHCONHR1, -NHCOR1R2, NR1CONR1R2, (NH2)n, -NH2CH2, NH2CH2CF3, -CH(CF3)-(CH)n- CO-N-R1R2, CH(CF3)-(CH)n-SO2, (CH)n;CH(OH)(CF3)(heterocycle)R1, an optionally substituted 3-8 membered carbocyclic ring, or a 3-8 membered saturated, mono, fused or bridged heterocyclic ring containing 1-3 heteroatoms or SO2 selected from the group including O, N, S, an optionally substituted 3-8 membered heterocyclic ring containing 1-3 heteroatoms or SO2 selected from the group including O, N, S, the substitutions being independently selected from the ring; C 1-6 Alkaril, ArC 1-6 R1 and R2 may be at any position of the alkyl; R1 and R2 are independently selected from the group consisting of H, halo, CN, CF3, hydroxyl, amino, SO2, SO2, C1-C6 alkyl, SO2-C3-C8-cycloalkyl, CH2CN, CH2CF3, unsubstituted or substituted C1-C6 straight or branched alkyl, the substituents being halo, OH, CN, C1-C6 alkoxy, optionally substituted NH2, C1-C6 alkylsulfonyl, optionally substituted CONH2, unsubstituted or substituted C3-C8 carbocyclyl or a 3-8 membered heterocyclic ring having 1-3 heteroatoms selected from O, N and S, SO2, C1-C6 straight or branched alkenyl, C1-C6 straight or branched alkynyl, C1-C6 alkyloxy; C1-C6 alkylamino, C1-C 6 alkylcarbonyl, C(O)-C3-C8-cycloalkyl, heteroalkyl, optionally substituted CONH2, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C3-C8 heterocycloalkyl, C3-C8 heterocycloalkenyl, carbocyclyl, aryl, and heteroaryl, -CH(CF3)-(CH)n-CO-N-R3R4, -CH(CF3)-(CH)n-SO2-NR3R4, CH(CF3)-(CH)n-NR3R4, CH(CF3)-(CH)n-SO2-CHR3R4, wherein the cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, carbocyclyl, aryl, and heteroaryl groups may be optionally substituted; R3 and R4 are H, independently CH3, C3-C8 cycloalkyl; R5 is an unsubstituted or substituted 3- to 8-membered carbocyclic ring or heterocyclic ring containing 1 to 3 heteroatoms selected from the group including O, N, and S, SO2; R6 is independently H, C1-C6 straight or branched alkyl, halogen; X can be linked to Y at any atom to arrive at a chemically viable bond; n is 0 to 3.
[0013] The present invention discloses novel compounds of 1H-imidazo[4,5-b]pyridin-2(3H)-ones of formula III, their pharma- ceutically acceptable salts and isomers. [ka] [In the formula, Y may be present at any position on the pyridine ring, preferably at the 4- or 5-position of the pyridine; Y is H, R1, R2, halo, CN, -CO-, COR1, (CH2)n, -(CH2)nCN-, CH2CF3, COOH, -COOR1, -CON(R1)2, -SO2(CH2)n, -SO 2N(R1)2, -OCOR1, -NR1COR1, -CONH, CONR1R2, -CO(NH2)n(CH2)nSO2;-CONH(CH2)nOH, CONH(CH2)nSO2R1R2 , -CONH-(CH2)nCF3, -CONH(CH2)nCF3, -NHCONH(CH2)nCF3, -CH(CF3)-(CH)n-CO-N-R1R2, CH(CF3)-(CH)n- SO2-(CH)n; CH(OH)(CF3) (heterocycle) R1, NHCONHR1, -NHCOR1R2, NR1CONR1R2, (NH2)n, -NH2CH2-, NH2CH2CF3, Heterocycle is an optionally substituted 3-8 membered saturated, mono, fused or bridged heterocyclic ring containing 1-3 heteroatoms selected from the group including O, N, S; The substitutions are independently a heterocyclic ring; 1-6 Alkaril, ArC 1-6 R1 and R2 may be at any position of the alkyl; R1 and R2 are absent or independently selected from the group including H, halo, CN, CF3, hydroxyl, amino, SO2, SO2C1-C6 alkyl, CH2CF3, C1-C6 straight or branched alkyl, C1-C6 straight or branched alkenyl, C1-C6 straight or branched alkynyl, halo-C1-C6 alkyl, C1-C6 alkyloxy; C1-C6 alkylamino; n is 0 to 3.
[0014] The present invention discloses exemplary compounds of formula III as follows: 1133. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylpiperidin-4-yl)ethanol; 1134. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(tetrahydro-2H-pyran-4-yl)ethanol; 1176. 1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carbonyl)pyrrolidine-3-carbonitrile 1181.7-(1-(5-((S)-1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 1182.7-(1-(5-((R)-1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 1225.(R)-1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-isopropylpyrrolidin-3-yl)ethanol 1226.(S)-1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-isopropylpyrrolidin-3-yl)ethanol 1231. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylazetidin-3-yl)ethanol
[0015] In one embodiment, the present invention also discloses methods for preparing the compounds of the present invention. The compounds of the present invention can be prepared according to the general synthetic schemes 1-4 presented herein below:
[0016] General synthetic scheme 1: [ka] X is C, N, R2 and R3 are H; R1 is, [ka] and X is C, N, R1 is CN and R2 is H; R3 is, [ka] and X is C, N, R1 is CF3 and R2 is H; R3 is, [ka] and X is C, N, R1 is CF3 and R2 is OH; R3 is [ka] and X is C, N, R1 is CF3 and R2 is OCH3; R3 is [ka] It is.
[0017] General synthetic scheme 2: [ka] X1=O or H, R2=H or -CH3, and R3=H or -CH3; R1 is, [ka] and R4 is [ka] It is.
[0018] General synthetic scheme 3: [ka] X1, Y, and Z are C and N. R3 is H, O, carbocycle, [ka] It is.
[0019] General synthetic scheme 4: [ka] X is C,N. R2 is H, O, or a carbocycle; R1= [ka] It is.
[0020] The present invention also includes, as another embodiment, a composition comprising a JAK1 inhibitor compound according to any one of the preceding embodiments together with a pharma- ceutically acceptable diluent, excipient, and / or carrier. The composition comprises a conventional pharmaceutical carrier, excipient, and / or diluent, and a compound of the present disclosure as the / an active agent, and may additionally include carriers, adjuvants, and the like. A pharma- ceutically acceptable composition contains about 1% to about 99% by weight of a compound of the present disclosure, or a pharma- ceutically acceptable salt thereof, and 99% to 1% by weight of a suitable pharmaceutical excipient.
[0021] Administration of the compounds of the present disclosure, or their pharma- ceutically acceptable salts, in pure form or in suitable pharmaceutical compositions can be via any of the recognized modes of administration or pharmacy that provide similar utility. Thus, administration can be, for example, oral, nasal, parenteral (intravenous, intramuscular, or subcutaneous), topical, transdermal, vaginal, Intravesical The pharmaceutical compositions can be administered intravenously, intracisternally, or rectally in solid, semi-solid, lyophilized powder, or liquid dosage forms, such as tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, preferably in unit dosage forms suitable for easy administration of precise doses.
[0022] The solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. The solid dosage forms as described above can be prepared with coatings and shells, such as enteric coatings. The liquid dosage forms for oral administration include pharma-ceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. The compositions for rectal administration are, for example, suppositories, which can be prepared by mixing the compounds of the present disclosure with suitable non-irritating excipients or carriers. They are also parenteral, and are administered as sterile powders that are reconstituted into injectable sterile solutions or dispersions. The dosage forms for topical administration of the compounds of the present disclosure include ointments, powders, and sprays. Ophthalmic preparations, eye ointments, powders, inhalation preparations, and solutions are also envisioned for the compounds of the present disclosure. Compressed gas can be used to disperse the compounds of the present disclosure in aerosol form.
[0023] The present invention includes, as a further embodiment, a method for treating a JAK1-mediated or -associated disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a JAK1 inhibitor compound according to any one of the preceding embodiments, or a composition comprising a JAK1 inhibitor according to any one of the preceding embodiments, together with a pharma- ceutically acceptable diluent, excipient, and / or carrier. JAK1-mediated or -associated diseases that can be treated include, without limitation, cancer, inflammatory disorders, and autoimmune diseases.
[0024] The selective JAK1 inhibitors of the present invention may be effective in treating cancers, including but not limited to, carcinomas, sarcomas, lymphomas, leukemias, myelomas, germ cell tumors, blastomas, tumors of the central and peripheral nervous system, and other tumors, including melanomas, seminomas, and Kaposi's sarcoma.
[0025] The compounds of the invention may also be useful in disorders and diseases associated with AIDS, Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, asthma, autoimmune hemolytic anemia, autoimmune thyroiditis, Crohn's disease, episodic lymphocytopenia with lymphocytotoxic factors, erythroblastosis fetalis, Goodpasture's syndrome, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome and other intestinal diseases, lupus, myasthenia gravis, myocardial or pericardial inflammation, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, scleroderma, systemic analphylaxis, ulcerative colitis, nephritis (including glomerulonephritis), gout, arthritis (e.g., rheumatoid arthritis and osteoarthritis), erythema, dermatitis, dermatomyositis, bronchitis, cholecystitis, sepsis and gastritis. Without being limited by theory, the compounds of the present invention exhibit selective inhibition of JAK1 relative to JAK2, JAK3 and TYK2. Thus, the compounds of the present invention are proposed to be more specific and advantageous than other compounds of the prior art because they demonstrate selective inhibition and are therefore expected to produce fewer adverse effects.
[0026] The following examples and schemes represent general synthetic procedures for the compounds disclosed herein. The synthesis of the compounds of formula I disclosed herein and its embodiments are not limited by these examples and schemes. Those skilled in the art will recognize that other procedures can be used to synthesize the compounds of formula I disclosed herein, and the procedure described in the examples and schemes is only one of such procedures. In the following description, those skilled in the art will recognize that the specific reaction conditions, added reagents, solvents, and reaction temperatures can be modified for the synthesis of specific compounds within the scope of this disclosure. All intermediate compounds described below, unless otherwise stated, are commercially available compounds for those compounds that are not described in the following examples on how to synthesize such intermediates.
[0027] Compound No. 1177: Synthesis of 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)acetonitrile [ka] Step-1: Synthesis of tert-butyl 3-hydroxypyrrolidine-1-carboxylate: [ka] To a stirred solution of tert-butyl 3-oxopyrrolidine-1-carboxylate (0.50 g, 2.699 mmol) in ethanol (5 mL) was added sodium borohydride (0.20 g, 5.399 mmol) at 0° C. and the mixture was stirred at room temperature for 4 h. The progress of the reaction was monitored by TLC. After completion of the reaction, water (10 mL) was added to the reaction mixture and the product was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated under reduced pressure to give tert-butyl 3-hydroxypyrrolidine-1-carboxylate (0.5 g, 99%) as a yellow solid. MS:188.24[M+1]
[0028] Step-2: Synthesis of 1-(tert-butoxycarbonyl)pyrrolidin-3-yl methanesulfonate [ka] To a stirred solution of tert-butyl 3-hydroxypyrrolidine-1-carboxylate (1.0 g, 5.347 mmol) in DCM (10.0 mL) was added MsCl (0.673 g, 5.882 mmol) at 0° C. under nitrogen. To the resulting reaction mixture was added dropwise a solution of DIPEA (0.898 g, 6.951 mmol) in DCM (1.0 mL) and stirred at room temperature for 4 h and the progress of the reaction was monitored by TLC. On completion, it was quenched with water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 10% ethyl acetate in hexane as eluent to give 1-(tert-butoxycarbonyl)pyrrolidin-3-yl methanesulfonate (0.25 g, 25%) as a crude yellow oily mass. MS:266.33[M+1]
[0029] Step-3: Synthesis of tert-butyl 3-cyanopyrrolidine-1-carboxylate [ka] To a stirred solution of 1-(tert-butoxycarbonyl)pyrrolidin-3-yl methanesulfonate (0.25 g, 0.9432 mmol) in DMF (5 mL) and water (1 mL) under nitrogen, KCN (0.138 g, 2.830 mmol) was added and the resulting solution was heated at 80° C. overnight. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was cooled to 0° C. and quenched with water. The product was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 6% acetone / hexane as eluent to give tert-butyl 3-cyanopyrrolidine-1-carboxylate (0.15 g, 81%) as a yellow oil. MS: 197.25 [M+1]
[0030] Step-4: Synthesis of pyrrolidine-3-carbonitrile trifluoroacetate [ka] To a stirred solution of tert-butyl 3-cyanopyrrolidine-1-carboxylate (0.15 g, 0.765 mmol) in DCM (5 mL) was added TFA (0.8 mL) at 0° C. and the reaction was allowed to stir at room temperature for 4 h. The reaction was monitored by TLC. Upon completion, all volatiles were evaporated under reduced pressure and the residue was triturated with diethtyl ether, filtered and dried to give pyrrolidine-3-carbonitrile trifluoroacetate (0.1 g, 62.2%) as a light brown solid. MS:194.15[M+1]
[0031] Step-5: Synthesis of 4-nitrophenyl 3-cyanocyclopentanecarboxylate [ka] To a stirred solution of pyrrolidine-3-carbonitrile trifluoroacetate (0.05 g, 0.238 mmol) in ACN (5.0 mL) was added trimethylamine (0.072 g, 0.714 mmol) followed by 4-nitrophenyl chloroformate (0.047 g, 0.238 mmol) at 0° C. The resulting reaction mixture was stirred at room temperature for 4 h. The reaction was monitored by TLC for completion. Upon completion, the product was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure to give 4-nitrophenyl 3-cyanocyclopentanecarboxylate (0.05 g, 80.5%) as a white solid. MS:261.25[M+1]
[0032] Step-6: Synthesis of 1-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazole-1-carbonyl)pyrrolidine-3-carbonitrile [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.05 g, 0.2439 mmol) in DMF (2 mL) was added NaH (0.02 g, 0.4878 mmol) under nitrogen at 0° C. and stirred at the same temperature for 30 min. To the resulting reaction mass was added a solution of 4-nitrophenyl 3-cyanocyclopentanecarboxylate (0.094 g, 0.7894 mmol) in DMF at 0° C. and stirred at room temperature for 4 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 0.5% methanol in DCM as the eluent to give 1-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazole-1-carbonyl)pyrrolidine-3-carbonitrile (0.03 g, 37.6%) as a yellow solid. MS:328.3[M+1]
[0033] Step-7: Synthesis of 1-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazole-1-carbonyl)pyrrolidine-3-carbonitrile [ka] A stirred solution of 1-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazole-1-carbonyl)pyrrolidine-3-carbonitrile (0.03 g, 0.0917 mmol) in methanol (5 mL) was hydrogenated over 10% Pd / C (0.003 g, 10% w / w) using a hydrogen balloon. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was filtered through Celite and the filtrate was evaporated under reduced pressure to give 2-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)acetonitrile (0.02 g, 73.5%) as a brown solid. MS:298.3[M+1]
[0034] Step-8: Synthesis of 1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carbonyl)pyrrolidine-3-carbonitrile [ka] To a stirred solution of 2-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)acetonitrile (0.025 g, 0.0841 mmol) was added trimethyl orthoformate (1.0 mL). To the resulting reaction mixture was added PTSA (0.004 g) and stirred at 70° C. for 4 hours. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous sodium bicarbonate and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent of 3%-5% MeOH in DCM to give 1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carbonyl)pyrrolidine-3-carbonitrile (0.01 g, 40%) as an off-white solid. MS:308.3[M+1]
[0035] Compound No. 1056: Synthesis of N-(3-cyanocyclobutyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide [ka] Step-1: Synthesis of tert-butyl 3-carbamoylcyclobutylcarbamate: [ka] To a stirred solution of tert-butyl 3-cyanopyrrolidine-1-carboxylate (0.500 g, 2.325 mmol) in THF (15 mL) was added ethyl chloroformate (0.301 mg, 2.79 mmol) at 0° C. and the reaction was allowed to stir at room temperature for 1 h. To the resulting reaction mass was added ammonium hydroxide solution (5.0 mL) at 0° C. and stirred at room temperature for 4 h. The reaction was monitored by TLC. Upon completion, the product was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure to give the resulting tert-butyl 3-carbamoylcyclobutylcarbamate (0.430 g, 85.65%) as a colorless liquid. MS:215.12[M+1]
[0036] Step-2: Synthesis of tert-butyl 3-cyanocyclobutylcarbamate: [ka] To a stirred solution of tert-butyl 3-carbamoylcyclobutylcarbamate (0.400 g, 1.869 mmol) in pyridine (5.0 mL) was added POCl3 (1.84 g, 1.200 mmol) at 0° C. and the reaction was allowed to stir at room temperature for 1 h. The reaction was monitored by TLC. Upon completion, the product was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and concentrated under reduced pressure to give the resulting tert-butyl 3-cyanocyclobutylcarbamate (0.340 g, 98.8%) as a colorless liquid. MS:197.15[M+1]
[0037] Step-3: Synthesis of 3-aminocyclobutanecarbonitrile hydrochloride: [ka] To a stirred solution of tert-butyl 3-cyanocyclobutylcarbamate (0.300 g, 1.522 mmol) in DCM (5 mL) was added dioxane-HCl (2.5 mL) at 0° C. and the reaction was allowed to stir at room temperature for 4 h. The reaction was monitored by TLC. Upon completion, all volatiles were evaporated under reduced pressure and the residue was triturated with di-ethyl ether, filtered and dried to give 3-aminocyclobutanecarbonitrile hydrochloride (0.240 g, 94.63%) as an off-white solid. MS:133.05[M+1]
[0038] Step-4: Synthesis of 4-nitrophenyl 3-cyanocyclobutylcarbamate [ka] To a stirred solution of 3-aminocyclobutanecarbonitrile hydrochloride (0.300 g, 2.247 mmol) in ACN (5.0 mL) was added trimethylamine (0.493 g, 4.89 mmol) followed by 4-nitrophenyl chloroformate (0.544 g, 2.706 mmol) at 0° C. The resulting reaction mixture was stirred at room temperature for 4 h. The reaction was monitored by TLC for completion. Upon completion, the product was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure to give 4-nitrophenyl 3-cyanocyclobutylcarbamate (0.250 g, 42.23%) as a yellowish solid. MS:262.05[M+1]
[0039] Step-5: Synthesis of N-(3-cyanocyclobutyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide [ka] To a stirred solution of 7-(1H-pyrazol-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one hydrochloride (0.05 g, 0.210 mmol) in ACN (2.5 mL) was added TEA (0.053 g, 0.527 mmol) under nitrogen at 0° C. and stirred at the same temperature for 30 min. To the resulting reaction mass was added a solution of 4-nitrophenyl 3-cyanocyclobutylcarbamate (0.081 g, 0.315 mmol) in ACN under nitrogen at 0° C. followed by TEA (0.035 g, 0.315 mmol) and stirred at room temperature for 4 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 3-5% methanol in DCM as the eluent to give N-(3-cyanocyclobutyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide (0.03 g, 37.6%) as an off-white solid. MS:324.11[M+1]
[0040] Compound No. 1063: Synthesis of N-(cyano(phenyl)methyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide [ka] Step-1: 2-Amino-2-phenylacetonitrile [ka] To a stirred solution of benzaldehyde (1.0 g, 0.934 mmol) in ethanol (20 mL) was added ammonium chloride (0.99 g, 1.86 mmol), ammonium hydroxide (12.5 ml, 25%) and potassium cyanide (0.78 g, 1.21 mmol) at room temperature. The resulting reaction mixture was stirred at the same temperature for 4 hours. The completion of the reaction was monitored by TLC. Upon completion, it was quenched with ice water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give 2-amino-2-phenylacetonitrile (0.600 g, 48.3%) as an orange solid. MS:133.04[M+1]
[0041] Step-2: 4-Nitrophenylcyano(phenyl)methylcarbamate [ka] To a stirred solution of 2-amino-2-phenylacetonitrile (0.200 g, 1.515 mmol) in chloroform (5.0 mL) was added pyridine (0.3 g, 3.03 mmol) followed by 4-nitrophenyl chloroformate (0.3 g, 1.515 mmol) at 0° C. The resulting reaction mixture was stirred at room temperature for 4 h. The reaction was monitored by TLC for completion. Upon completion, the product was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure to give 4-nitrophenyl cyano(phenyl)methylcarbamate (0.200 g, 44.4%) as a white solid. MS:298.25[M+1]
[0042] Step-3: Synthesis of N-(cyano(phenyl)methyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide [ka] To a stirred solution of 7-(1H-pyrazol-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one hydrochloride (0.030 g, 0.0127 mmol) in DMF (2.0 mL) was added trimethylamine (0.038 g, 0.0381) and 4-nitrophenylcyano(phenyl)methylcarbamate (0.037 g, 0.0127 mmol). The resulting reaction mixture was stirred at room temperature for 6 hours. The reaction was monitored by TLC for completion. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent: 8-9% MeOH in DCM to give N-(cyano(phenyl)methyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide (0.004 g, 8.7%) as an off-white solid. MS:360.1[M+1]
[0043] Compound No. 1064: Synthesis of -N-(2,2,2-trifluoroethyl)-4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide [ka] Step-1: Synthesis of 4-(2-amino-3-nitropyridin-4-yl)-N-(2,2,2-trifluoroethyl)-1H-pyrazole-1-carboxamide [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.150 g, 0.073 mmol) in acetonitrile (10 mL) and trimethylamine (0.147 g, 0.146 mmol) was added 4-nitrophenyl 2,2,2-trifluoroethylcarbamate (0.231 g, 0.087 mmol) at room temperature. The resulting reaction mixture was stirred at a temperature of 60° C. for 6 hours. Completion of the reaction was monitored by TLC. Upon completion, it was quenched with ice water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to obtain the crude reaction mass. Purification of the crude product was carried out via silica gel (100-200 mesh) column chromatography, and the desired compound was eluted with 3-4% methanol in DCM to give 4-(2-amino-3-nitropyridin-4-yl)-N-(2,2,2-trifluoroethyl)-1H-pyrazole-1-carboxamide (0.160 g, 67%) as a yellow solid. MS:331.04[M+1]
[0044] Step-2: Synthesis of 4-(2,3-diaminopyridin-4-yl)-N-(2,2,2-trifluoroethyl)-1H-pyrazole-1-carboxamide [ka] To a stirred solution of 4-(2-amino-3-nitropyridin-4-yl)-N-(2,2,2-trifluoroethyl)-1H-pyrazole-1-carboxamide (0.080 g, 0.024 mmol) in EtOH (3.0 mL) was added NH4Cl (2.0 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.064 g, 0.12 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with H2O:EtOAc (50 mL, 5:5) and passed through Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give 4-(2,3-diaminopyridin-4-yl)-N-(2,2,2-trifluoroethyl)-1H-pyrazole-1-carboxamide (0.045 g, 62.5%) as a dark brown solid mass. MS:301.2[M+1]
[0045] Step-3: Synthesis of N-(2,2,2-trifluoroethyl)-4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide [ka] To a stirred solution of 4-(2,3-diaminopyridin-4-yl)-N-(2,2,2-trifluoroethyl)-1H-pyrazole-1-carboxamide (0.045 g, 0.015 mmol) in THF (1.0 mL) was added trimethyl orthoformate (2.0 mL). To the resulting reaction mixture was added PTSA (0.0051 g, 0.0030 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 8-9% MeOH in DCM to give N-(2,2,2-trifluoroethyl)-4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide (0.023 g, 50%) as an off-white solid. MS:311.1[M+1]
[0046] Compound No. 1119: Synthesis of 7-(1-(5-(2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine [ka] Step-1: Synthesis of 6-bromopyridine-3-carbaldehyde: [ka] To a stirred solution of 2,5-dibromopyridine (26.0 g, 109.75 mmol) in diethyl ether (500 mL) was added n-butyllithium (2.5 M in hexane) (66 mL, 164.63 mmol) under nitrogen at −78° C. and stirred at the same temperature for 1 h. Then DMF (13 mL, 164.63 mmol) was added dropwise to the reaction mixture and stirred at −78° C. for 1 h. The progress of the reaction was monitored by TLC. After completion of the reaction the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with diethyl ether. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 4% ethyl acetate in hexane as the eluent to give 6-bromopyridine-3-carbaldehyde (12.20 g, 59.8%) as a yellow oil. MS:187.0[M+1]
[0047] Step-2: Synthesis of 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethanol [ka] To a stirred solution of 6-bromopyridine-3-carbaldehyde (2.0 g, 10.75 mmol) in DME (50 mL) under nitrogen at 0° C., TMSCF3 (1.61 g, 16.12 mmol) was added followed by portionwise addition of CsF (2.44 g, 16.12 mmol) and stirred at the same temperature for 1 h. It was allowed to warm to room temperature and stirred for 6 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (100-200 mesh) using 20% ethyl acetate in hexane as the eluent to give 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethanol (1.24 g, 47.69%) as a yellow oil. MS:257.8[M+1]
[0048] Step-3: Synthesis of 2-bromo-5-(2,2,2-trifluoro-1-methoxyethyl)pyridine [ka] To a stirred solution of 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethanol (0.40 g, 15.56 mmol) in THF (5.0 mL) was added NaH (0.081 g, 20.23 mmol) under nitrogen at 0° C. and stirred at the same temperature for 1 h. To the resulting reaction mass was added MeI (0.232 g, 20.23 mmol) solution in THF (3.0 mL), warmed to room temperature and stirred for 1 h. The reaction progress was monitored by TLC. After completion of the reaction the reaction mass was quenched with ice cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 10% acetone in hexane as the eluent to give 2-bromo-5-(2,2,2-trifluoro-1-methoxyethyl)pyridine (0.39 g, 92.19%) as a colorless oil. MS:271.0[M+1]
[0049] Step-4: Synthesis of 4-(1-(5-(2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.15 g, 0.73 mmol) and compound 2-bromo-5-(2,2,2-trifluoro-1-methoxyethyl)pyridine (0.278 g, 1.02 mmol) in DMSO (5 ml) was added K2CO3 (0.251 g, 1.825 mmol), followed by CuI (0.013 g, 0.073 mmol) and L-proline (0.056 g, 0.365 mmol). The reaction was heated at 110° C. for 16 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent 40-60% acetone in n-hexane to give 4-(1-(5-(2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.075 g, 37.87%) as a yellow solid. MS:394.4[M+1]
[0050] Step-5: Synthesis of 4-(1-(5-(2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine [ka] To a stirred solution of 4-(1-(5-(2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.070 g, 1.77 mmol) in EtOH (3.0 mL) was added NH4Cl (2.5 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.025 g, 0.45 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with HO:EtOAc (50 mL, 5:5) and passed through Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give pure 4-(1-(5-(2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.035 g, 53.03%) as a dark brown solid mass. MS:364.2[M+1]
[0051] Step-6: Synthesis of 7-(1-(5-(2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine [ka] To a stirred solution of 4-(1-(5-(2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.035 g, 0.093 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.002 g, 0.018 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent of 3%-5% MeOH in DCM to give 7-(1-(5-(2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (0.07 g, 19.44%) as an off-white solid. MS:375.9[M+1]
[0052] Compound No. 1126: Synthesis of 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-cyclopropyl-2,2,2-trifluoroethanol [ka] Step-1: Synthesis of N-methoxy-N-methylcyclopropanecarboxamide: [ka] To a stirred solution of cyclopropanecarbonyl chloride (10.0 g, 961.5 mmol) and N-methoxymethanamine hydrochloride (11.20 g, 1153.8 mmol) in THF (150 mL), TEA (24.20 g, 2403.8 mmol) was added dropwise at 0° C. and allowed to stir for 30 min. The resulting reaction mass was then placed at room temperature and stirred for 4 h. The reaction completion was monitored by TLC. Upon completion, it was concentrated under reduced pressure to give a crude product mass. Purification of the crude product was carried out via silica gel (100-200 mesh) column chromatography and the desired compound was eluted with 5% ether / n-hexane to give N-methoxy-N-methylcyclopropanecarboxamide (7.45 g, 60%) as a colorless oily mass. MS:130.07[M+1]
[0053] Step-2: Synthesis of (6-bromopyridin-3-yl)(cyclopropyl)methanone: [ka] To a stirred solution of 2,5-dibromopyridine (12.0 g, 50.63 mmol) in diethyl ether (250 mL) was added n-butyllithium (2.5 M in hexane) (24.30 mL, 65.81 mmol) at −78° C. under nitrogen and stirred at the same temperature for 1 h. Then N-methoxy-N-methylcyclopropanecarboxamide (7.1 g, 55.69 mmol) was added dropwise to the reaction mixture and stirred at −78° C. for 1 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with diethyl ether. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 4% ethyl acetate in hexane as the eluent to give (6-bromopyridin-3-yl)(cyclopropyl)methanone (6.46 g, 68.07%) as a yellow oil. MS:227.1[M+1]
[0054] Step-3: Synthesis of 1-(6-bromopyridin-3-yl)-1-cyclopropyl-2,2,2-trifluoroethanol [ka] To a stirred solution of (6-bromopyridin-3-yl)(cyclopropyl)methanone (2.0 g, 88.49 mmol) in DME (25 mL) under nitrogen at 0° C., TMSCF3 (1.86 g, 132.74 mmol) was added followed by portionwise addition of CsF (2.01 g, 132.74 mmol) and stirred at the same temperature for 1 h. It was allowed to warm to room temperature and stirred for 6 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (100-200 mesh) using 15-20% ethyl acetate in hexanes as the eluent to give 1-(6-bromopyridin-3-yl)-1-cyclopropyl-2,2,2-trifluoroethanol (1.45 g, 55.76%) as a yellow oil. MS:297.4[M+1]
[0055] Step-4: Synthesis of 1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-cyclopropyl-2,2,2-trifluoroethanol [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.15 g, 0.73 mmol) and compound 1-(6-bromopyridin-3-yl)-1-cyclopropyl-2,2,2-trifluoroethanol (0.320 g, 1.02 mmol) in DMSO (5 ml) was added K2CO3 (0.251 g, 1.825 mmol), followed by CuI (0.013 g, 0.073 mmol) and L-proline (0.056 g, 0.365 mmol). The reaction was heated at 110° C. for 12 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 40-60% acetone in n-hexane to give 1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-cyclopropyl-2,2,2-trifluoroethanol (0.065 g, 21.10%) as a yellow solid. MS:421.37[M+1]
[0056] Step-5: Synthesis of 1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-cyclopropyl-2,2,2-trifluoroethanol [ka] To a stirred solution of 1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-cyclopropyl-2,2,2-trifluoroethanol (0.065 g, 1.54 mmol) in EtOH (3.0 mL) was added NH4Cl (2.5 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.043 g, 7.8 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with HO:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give 1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-cyclopropyl-2,2,2-trifluoroethanol (0.035 g, 57.37%) as a dark brown solid mass. MS:391.2[M+1]
[0057] Step-6: Synthesis of 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-cyclopropyl-2,2,2-trifluoroethanol [ka] To a stirred solution of 1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-cyclopropyl-2,2,2-trifluoroethanol (0.035 g, 0.089 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.003 g, 0.0017 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent 3%-5% MeOH in DCM to give 7-(1-(5-(2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (0.06 g, 17.19%) as an off-white solid. MS:400.9[M+1]
[0058] Compound No. 1128: Synthesis of 7-(1-(5-(1,1,1,2-tetrafluoropropan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine [ka]
[0059] Step-1: Synthesis of 1-(6-bromopyridin-3-yl)ethanone: [ka] To a stirred solution of 2,5-dibromopyridine (12.0 g, 50.63 mmol) in diethyl ether (250 mL) was added n-butyllithium (2.5 M in hexane) (24.30 mL, 65.81 mmol) at −78° C. under nitrogen and stirred at the same temperature for 1 h. Then DMA (7.89 g, 60.75 mmol) was added dropwise to the reaction mixture and stirred at −78° C. for 1 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with diethyl ether. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 4% ethyl acetate in hexane as the eluent to give 1-(6-bromopyridin-3-yl)ethanone (4.5 g, 44.03%) as a yellow oil. MS:201.1[M+1]
[0060] Step-2: Synthesis of 2-(6-bromopyridin-3-yl)-1,1,1-trifluoropropan-2-ol [ka] To a stirred solution of 1-(6-bromopyridin-3-yl)ethanone (2.0 g, 11.00 mmol) in DME (50 mL) under nitrogen at 0° C., TMSCF3 (2.33 g, 14.30 mmol) was added followed by CsF (2.50 g, 16.50 mmol) in portions and stirred at the same temperature for 1 h. It was allowed to warm to room temperature and stirred for 6 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (100-200 mesh) using 15-20% ethyl acetate in hexane as the eluent to give 2-(6-bromopyridin-3-yl)-1,1,1-trifluoropropan-2-ol (1.45 g, 53.50%) as a yellow oil. MS:271.0[M+1]
[0061] Step-3: Synthesis of 2-bromo-5-(1,1,1,2-tetrafluoropropan-2-yl)pyridine [ka] To a stirred solution of 2-(6-bromopyridin-3-yl)-1,1,1-trifluoropropan-2-ol (1.45 g, 53.70 mmol) in DCE (35 mL) under nitrogen at 0° C., DAST (1.12 g, 69.81 mmol) was added, followed by stirring at the same temperature for 15 min. It was allowed to warm to room temperature and stirred for 1 h. The reaction progress was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (100-200 mesh) using 15-20% ethyl acetate in hexane as the eluent to give 2-bromo-5-(1,1,1,2-tetrafluoropropan-2-yl)pyridine (1.1 g, 75.86%) as a yellow oil. MS:273.04[M+1]
[0062] Step-4: Synthesis of 4-(1-(5-(1,1,1,2-tetrafluoropropan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.15 g, 0.73 mmol) and compound 2-bromo-5-(1,1,1,2-tetrafluoropropan-2-yl)pyridine (0.298 g, 1.09 mmol) in DMSO (5 ml) was added K2CO3 (0.251 g, 1.825 mmol), followed by CuI (0.013 g, 0.073 mmol) and L-proline (0.056 g, 0.365 mmol). The reaction was heated at 110° C. for 16 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography eluting with 40-60% acetone in n-hexane to give 4-(1-(5-(1,1,1,2-tetrafluoropropan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.065 g, 22.49%) as a yellow solid. MS:397.1[M+1]
[0063] Step-5: Synthesis of 4-(1-(5-(1,1,1,2-tetrafluoropropan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine [ka] To a stirred solution of 4-(1-(5-(1,1,1,2-tetrafluoropropan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.065 g, 0.16 mmol) in EtOH (3.0 mL) was added NH4Cl (2.5 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.041 g, 0.82 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with H2O:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give 4-(1-(5-(1,1,1,2-tetrafluoropropan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.035 g, 58.32%) as a dark brown solid mass. MS:367.4[M+1]
[0064] Step-6: Synthesis of 7-(1-(5-(1,1,1,2-tetrafluoropropan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine [ka] To a stirred solution of 4-(1-(5-(1,1,1,2-tetrafluoropropan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.035 g, 0.095 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.003 g, 0.0017 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent of 3%-5% MeOH in DCM to give 7-(1-(5-(1,1,1,2-tetrafluoropropan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (0.06 g, 16.67%) as an off-white solid. MS:377.2[M+1]
[0065] Compound No. 1164: Synthesis of (6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)(1-(methylsulfonyl)piperidin-4-yl)methanol [ka] Step-1: Synthesis of N-methoxy-N-methylcyclopropanecarboxamide: [ka] To a stirred solution of 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (10.0 g, 43.66 mmol) and N-methoxymethanamine hydrochloride (5.56 g, 56.76 mmol) in DMF (35 mL) was added DCC (13.51 g, 65.49 mmol) and DMAP (1.60 g, 13.98 mmol) sequentially at 0° C. and allowed to stir for 30 min. The resulting reaction mass was allowed to warm to room temperature and stirred for 4 h. The completion of the reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with 1N aqueous HCl and extracted with EtOAc. The organic layer was washed with aqueous bicarbonate, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent 20% acetone in n-hexane to give tert-butyl 4-(N-methoxy-N-methylcarbamoyl)piperidine-1-carboxylate (7.45 g, 60%) as a colorless oily mass. MS:273.1[M+1]
[0066] Step-2: Synthesis of tert-butyl 4-(6-bromonicotinoyl)piperidine-1-carboxylate [ka] To a stirred solution of 2,5-dibromopyridine (5.0 g, 21.18 mmol) in diethyl ether (100 mL) was added n-butyllithium (2.5 M in hexane) (8.47 mL, 21.18 mmol) at −78° C. under nitrogen and stirred at the same temperature for 1 h. Then tert-butyl 4-(N-methoxy-N-methylcarbamoyl)piperidine-1-carboxylate (6.36 g, 23.29 mmol) was added dropwise to the reaction mixture and stirred at −78° C. for 1 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with 10% MeOH in DCM. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure to give tert-butyl 4-(6-bromonicotinoyl)piperidine-1-carboxylate (5.8 g, 67.12%) as a colorless oily mass. MS:371.0[M+1]
[0067] Step-3: Synthesis of (6-bromopyridin-3-yl)(piperidin-4-yl)methanone: [ka] To a stirred solution of tert-butyl 4-(6-bromonicotinoyl)piperidine-1-carboxylate (5.0 g, 13.51 mmol) in THF (50 mL) was added 4M HCl in dioxane (25 mL) under nitrogen at 0° C. The reaction mixture was allowed to warm to room temperature and stirred for 10 h. Upon completion, the reaction mixture was quenched with bicarbonate solution and extracted with 10% MeOH in DCM. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 4-5% MeOH in DCM as the eluent to give (6-bromopyridin-3-yl)(piperidin-4-yl)methanone (3.45 g, 94.52%) as a colorless crystalline solid. MS:271.0[M+1]
[0068] Step-4: Synthesis of (6-bromopyridin-3-yl)(1-(methylsulfonyl)piperidin-4-yl)methanone [ka] To a stirred solution of (6-bromopyridin-3-yl)(piperidin-4-yl)methanone (2.0 g, 7.44 mmol) in dry DCM (20 mL) was added MsCl (1.11 g, 9.66 mmol) under nitrogen at 0° C. To the resulting reaction mixture was added TEA (1.12 g, 11.16 mmol) dropwise and stirred at 0° C. for 1 h. Warmed to room temperature and stirred for 1 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (100-200 mesh) using 2-3% ethyl MeOH in DCM as the eluent to give (6-bromopyridin-3-yl)(1-(methylsulfonyl)piperidin-4-yl)methanone (1.40 g, 56.00%) as an off-white solid. MS:349.01[M+1]
[0069] Step-5: Synthesis of (6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)(1-(methylsulfonyl)piperidin-4-yl)methanone [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.15 g, 0.73 mmol) and compound (6-bromopyridin-3-yl)(1-(methylsulfonyl)piperidin-4-yl)methanone (0.254 g, mmol) in DMA (5 ml) was added K2CO3 (0.251 g, 1.825 mmol). The reaction was heated at 110° C. for 6 h. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (100-200 mesh) using 4-5% MeOH in DCM as the eluent to give (6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)(1-(methylsulfonyl)piperidin-4-yl)methanone (0.065 g, 18.84%) as a yellow solid. MS:472.02[M+1]
[0070] Step-6: Synthesis of 1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-cyclopropyl-2,2,2-trifluoroethanol [ka] To a stirred solution of 1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-cyclopropyl-2,2,2-trifluoroethanol (0.065 g, 1.37 mmol) in EtOH (3.0 mL) was added NH4Cl (2.5 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.037 g, 6.8 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with HO:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give 1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-cyclopropyl-2,2,2-trifluoroethanol (0.035 g, 57.37%) as a dark brown solid mass. MS:442.0[M+1]
[0071] Step-7: Synthesis of (6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)(1-(methylsulfonyl)piperidin-4-yl)methanone [ka] To a stirred solution of 1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-cyclopropyl-2,2,2-trifluoroethanol (0.035 g, 7.93 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.003 g, 0.0017 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (100-200 mesh) using 5-6% MeOH in DCM as the eluent to give (6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)(1-(methylsulfonyl)piperidin-4-yl)methanone (0.006 g, 17.41%) as an off-white solid. MS:452.0[M+1]
[0072] Step-8: Synthesis of 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-cyclopropyl-2,2,2-trifluoroethanol [ka] To a stirred solution of (6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)(1-(methylsulfonyl)piperidin-4-yl)methanone (0.006 g, 0.013 mmol) in THF (1.0 mL) was added NaBH4 (0.001 g, 0.026 mmol) and stirred at 0° C. for 2 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with water and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give (6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)(1-(methylsulfonyl)piperidin-4-yl)methanol (0.03 g, 50.00%) as an off-white solid. MS:454.0[M+1]
[0073] Compound No. 1166: Synthesis of 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(1,1-dioxidethiomorpholino)acetonitrile [ka] Step-1: Synthesis of 6-bromopyridine-3-carbaldehyde: [ka] To a stirred solution of 2,5-dibromopyridine (26.0 g, 109.75 mmol) in diethyl ether (500 mL) was added n-butyllithium (2.5 M in hexane) (66 mL, 164.63 mmol) at −78° C. under nitrogen and stirred at the same temperature for 1 h. Then DMF (13 mL, 164.63 mmol) was added dropwise to the reaction mixture and stirred at −78° C. for 1 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with diethyl ether. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 4% ethyl acetate in hexane as the eluent to give 6-bromopyridine-3-carbaldehyde (12.20 g, 59.8%) as a yellow oil. MS:187.0[M+1]
[0074] Step-2: Synthesis of 6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridine-3-carbaldehyde [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.075 g, 0.36 mmol) and compound 6-bromopyridine-3-carbaldehyde (0.075 g, 0.40 mmol) in DMA (5 ml) was added K2CO3 (0.124 g, 0.90 mmol) and the reaction was heated at 110° C. for 16 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 1%-3% MeOH / DCM to give 6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridine-3-carbaldehyde (0.065 g, 51.58%) as a yellow solid. MS:311[M+1]
[0075] Step-3: 2-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(1,1-dioxidethiomorpholino)acetonitrile [ka] To a stirred solution of 6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridine-3-carbaldehyde (0.065 g, 0.20 mmol) in AcOH (5 mL) was added trimethyl silylcynide (TMSCN) (0.031 g, 0.31 mmol) and TMSCN (0.051 g, 0.38 mmol) in AcOH (1 mL) at 0° C. and allowed to warm to room temperature. Stirred for 16 h. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with aqueous bicarbonate and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 2-3% MeOH in DCM as eluent to give 2-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(1,1-dioxidethiomorpholino)acetonitrile (0.045 g, 47.36%) as a yellow solid. MS:454[M+1]
[0076] Step-4: 2-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(1,1-dioxidethiomorpholino)acetonitrile [ka] To a stirred solution of 2-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(1,1-dioxidethiomorpholino)acetonitrile (0.045 g, 0.09 mmol) in EtOH (10 mL) was added NH4Cl (2.5 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.027 g, 0.49 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with H2O:EtOAc 5:5 (50 mL) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give pure 2-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(1,1-dioxidethiomorpholino)acetonitrile (0.016 g, 37.20%) as a dark brown solid mass. MS:425.1[M+1]
[0077] Step-5: 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(1,1-dioxidethiomorpholino)acetonitrile [ka] To a stirred solution of 2-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(1,1-dioxidethiomorpholino)acetonitrile (0.016 g, 0.037 mmol) in THF (3.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.003 g, 0.07 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 4-6% MeOH in DCM as eluent to give 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(1,1-dioxidethiomorpholino)acetonitrile (0.03 g, 58.82%) as an off-white solid. MS:435.2[M+1]
[0078] Compound No. 1116: Synthesis of 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4-(methylsulfonyl)butanenitrile [ka] Step-1: Synthesis of 1-(6-bromopyridin-3-yl)-3-(methylthio)propan-1-ol: [ka] To a stirred solution of 2,5-dibromopyridine (1.5 g, 6.32 mmol) in diethyl ether (25 mL) was added n-butyllithium (2.5 M in hexane) (2.5 mL, 6.32 mmol) under nitrogen at −78° C. and stirred at the same temperature for 1 h. Then 3-(methylthio)propanal (0.73 g, 6.965 mmol) was added dropwise to the reaction mixture and stirred at −78° C. for 1 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with diethyl ether. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 4% ethyl acetate in hexane as the eluent to give 1-(6-bromopyridin-3-yl)-3-(methylthio)propan-1-ol (0.580 g, 35.15%) as a colorless oil. MS:264.0[M+1]
[0079] Step-2: Synthesis of 1-(6-bromopyridin-3-yl)-3-(methylsulfonyl)propan-1-ol: [ka] To a stirred solution of 1-(6-bromopyridin-3-yl)-3-(methylthio)propan-1-ol (0.58 g, 2.19 mmol) in acetone:H2O (50 mL, 7:3) under nitrogen at 0 °C, oxone (1.68 g, 5.49 mmol) was added and stirred at the same temperature for 16 h. The reaction progress was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 3% MeOH in DCM as eluent to give 1-(6-bromopyridin-3-yl)-3-(methylsulfonyl)propan-1-ol (0.60 g, 93.02%) as a colorless oil. MS:296.0[M+1]
[0080] Step-3: Synthesis of 1-(6-bromopyridin-3-yl)-3-(methylsulfonyl)propyl methanesulfonate: [ka] To a stirred solution of 2,5-dibromopyridine (0.30 g, 1.02 mmol) in DCM (5.0 mL) was added MsCl (0.151 g, 1.32 mmol) under nitrogen at 0° C. To the resulting reaction mixture was added dropwise a solution of TEA (0.153 g, 1.52 mmol) in DCM (1.0 mL) and stirred at 0° C. for 15 min. The temperature of the reaction mixture was slowly increased to room temperature and the progress of the reaction was monitored by TLC. Upon completion, it was quenched with water and extracted with ethyl acetate. The aqueous layer was basified with bicarbonate until pH paper was basic, then extracted with ethyl acetate, dried over sodium sulfate and concentrated under reduced pressure to give 1-(6-bromopyridin-3-yl)-3-(methylsulfonyl)propyl methanesulfonate (0.320 g, 84.43%) as a crude yellow oily mass. MS:374.02[M+1]
[0081] Step-4: Synthesis of 2-(6-bromopyridin-3-yl)-4-(methylsulfonyl)butanenitrile: [ka] To a stirred solution of 2,5-dibromopyridine (0.320 g, 8.56 mmol) in DMSO (1.5 mL) was added potassium cyanide (0.067 g, 10.27 mmol) at room temperature under nitrogen and stirred at 80 °C for 1 h. The reaction progress was monitored by TLC. After completion, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 2-3% MeOH in DCM as eluent to give 2-(6-bromopyridin-3-yl)-4-(methylsulfonyl)butanenitrile (0.120 g, 46.15%) as a dark brown sticky mass. MS:305.01[M+1]
[0082] Step-5: Synthesis of 2-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4-(methylsulfonyl)butanenitrile [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.07 g, 0.34 mmol) and compound 2-(6-bromopyridin-3-yl)-4-(methylsulfonyl)butanenitrile (0.155 g, 0.51 mmol) in dioxane (5 ml) was added K3PO4 (0.166 g, 0.78 mmol), followed by CuI (0.006 g, 0.034 mmol) and DMEDA (0.015 g, 0.175 mmol). The reaction was heated at 110° C. for 6 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 2-3% MeOH in DCM to give 2-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4-(methylsulfonyl)butanenitrile (0.030 g, 20.54%) as a yellow solid. MS:428.1[M+1]
[0083] Step-6: Synthesis of 2-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4-(methylsulfonyl)butanenitrile [ka] To a stirred solution of 2-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4-(methylsulfonyl)butanenitrile (0.030 g, 0.070 mmol) in EtOH (3.0 mL) was added NH4Cl (1.5 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.019 g, 0.35 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with HO:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give pure 4-(1-(5-(2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.015 g, 53.57%) as a dark brown solid mass. MS:398.2[M+1]
[0084] Step 7: Synthesis of 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4-(methylsulfonyl)butanenitrile [ka] To a stirred solution of 4-(1-(5-(2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.015 g, 0.037 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.0012 g, 0.018 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent of 3%-5% MeOH in DCM to give 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4-(methylsulfonyl)butanenitrile (0.004 g, 25.92%) as an off-white solid. MS:408.0[M+1]
[0085] Compound No. 1089: Synthesis of 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)nicotinoyl)azetidine-3-carbonitrile [ka] Step-1: Synthesis of methyl 6-bromopyridine-3-carboxylate [ka] To a stirred solution of 6-bromopyridine-3-carbaldehyde (1.5 g, 0.810 mmol) in methanol (45 mL) in the dark at room temperature, N-iodosuccinimide (2.72 g, 1.210 mmol) and base potassium carbonate (1.66 g, 1.210 mmol) were added and stirred at the same temperature for 6 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with saturated sodium thiosulfate solution, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 8-12% ethyl acetate in hexane as eluent to give methyl 6-bromopyridine-3-carboxylate (1.05 g, 59.8%) as a white solid. MS:215.0[M+1]
[0086] Step-2: Synthesis of methyl 6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridine-3-carboxylate [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.300 g, 0.138 mmol) and compound methyl 6-bromopyridine-3-carboxylate (0.44 g, 0.207 mmol) in DMA (7 ml) was added K2CO3 (0.381 g, 0.276 mmol) at room temperature. The reaction was heated at 110° C. for 16 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 40-60% acetone in n-hexane to give methyl 6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridine-3-carboxylate (0.210 g, 42.85%) as a yellow solid. MS:341.09[M+1]
[0087] Step-3: 6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridine-3-carboxylic acid [ka] To a stirred solution of methyl 6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridine-3-carboxylate (0.2 g, 0.058 mmol) in a mixture of THF:MeOH:H2O (18 mL, 5:3:1) was added LiOH (0.044 g, 0.117 mmol) and allowed to stir at room temperature for 2 h. On completion, all volatiles were evaporated under reduced pressure. The reaction mass was diluted with water, acidified with 6N HCl, adjusted to pH 6, and extracted with EtOAc. The organic portions were combined, dried over Na2SO4, and evaporated under reduced pressure to give 6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridine-3-carboxylic acid (0.170 g, 89%) as a yellow solid. MS:327[M+1]
[0088] Step-4: 1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)nicotinoyl)azetidine-3-carbonitrile [ka] To a stirred solution of 6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridine-3-carboxylic acid (0.080 g, 0.0271 mmol) and azetidine-3-carbonitrile hydrochloride (0.039 g, 0.049 mmol) in DMF (3 mL) was added HATU (0.139 g, 0.036 mmol), and DIPEA (0.063 g, 0.049 mmol). The reaction mixture was then stirred at room temperature for 6 h. The reaction was monitored by TLC. Upon completion, The reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and evaporated under reduced pressure to give the crude product. The crude product was purified by silica gel (100-200 mesh) column chromatography; eluent: 4% MeOH in DCM to give 1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)nicotinoyl)azetidine-3-carbonitrile (0.055 g, 58%) as a pale yellow solid. MS:391.09[M+1]
[0089] Step-5: 1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)nicotinoyl)azetidine-3-carbonitrile [ka] To a stirred solution of 1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)nicotinoyl)azetidine-3-carbonitrile (0.050 g, 0.012 mmol) in EtOH (3.0 mL) was added NH4Cl (2.5 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.033 g, 0.064 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with H2O:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give 1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)nicotinoyl)azetidine-3-carbonitrile (0.035 g, 76%) as a dark brown solid mass. MS:361.2[M+1]
[0090] Step-6: 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)nicotinoyl)azetidine-3-carbonitrile [ka] To a stirred solution of 1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)nicotinoyl)azetidine-3-carbonitrile (0.035 g, 0.097 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.003 g, 0.0017 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent of 5%-6% MeOH in DCM to give 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)nicotinoyl)azetidine-3-carbonitrile (0.018 g, 51.42%) as an off-white solid. MS:371.1[M+1]
[0091] Compound No. 1107: Synthesis of 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)propanenitrile [ka] Step-1: Synthesis of 2-(6-bromopyridin-3-yl)propanenitrile: [ka] To a stirred solution of 1-(6-bromopyridin-3-yl)ethanone (0.4 g, 0.20 mmol) in DME (12 mL) was added TosMIC (0.585 g 0.30 mmol) under inert conditions at 0° C. Then a solution of base potassium tert-butoxide (0.336 g, 0.30 mmol) in tert-butanol was added dropwise to the reaction mixture. After addition, the mixture was stirred at room temperature for 6 hours. The progress of the reaction was monitored by TLC. After completion, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 15% ethyl acetate in hexane as the eluent to give 2-(6-bromopyridin-3-yl)propanenitrile (0.240 g, 57.14%) as a colorless oil. MS:211[M+1]
[0092] Step-2: Synthesis of 2-(6-bromopyridin-3-yl)propanamide [ka] To a stirred solution of 2-(6-bromopyridin-3-yl)propanenitrile (0.240 g, 0.114 mmol) and DMSO (4 ml) was added basic potassium carbonate (0.315 g, 0.228 mmol) at 0° C. under N2. Hydrogen peroxide (0.7 ml) was added dropwise at 0° C. and the resulting mixture was stirred at room temperature for 4 h. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the pure product 2-(6-bromopyridin-3-yl)propanamide (0.230 g, 88.46%) as an off-white solid. MS:228[M+1]
[0093] Step-3: Synthesis of 2-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)propanamide: [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.160 g, 0.078 mmol) and compound 2-(6-bromopyridin-3-yl)propanamide (0.200 g, 0.078 mmol) in DMSO (5 ml) was added K2CO3 (0.215 g, 0.156 mmol), followed by CuI (0.029 g, 0.00156 mmol) and L-proline (0.017 g, 0.00156 mmol). The reaction was heated at 110° C. for 6 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 6-7% MeOH in DCM to give 2-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)propanamide (0.140 g, 45.45%) as a yellow solid. MS:354.1[M+1]
[0094] Step-4: Synthesis of 2-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)propanamide [ka] To a stirred solution of 2-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)propanamide (0.140 g, 0.039 mmol) in EtOH (7.0 mL) was added NH4Cl (2.0 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.105 g, 0.198 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with H2O:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give pure 2-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)propanamide (0.090 g, 70%) as a dark brown solid mass. MS:324.2[M+1]
[0095] Step-5: Synthesis of 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)propanamide: [ka] To a stirred solution of 2-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)propanamide (0.090 g, 0.0278 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.0095 g, 0.0055 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 8-9% MeOH in DCM to give 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)propanamide (0.048 g, 52.17%) as an off-white solid. MS:334.1[M+1]
[0096] Step-6: Synthesis of 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)propanenitrile: [ka] To a stirred solution of 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)propanamide (0.040 g, 0.0120 mmol) in pyridine (3.0 mL) was added POCl3 (0.091 g, 0.60 mmol) dropwise at 0° C. After addition, it was stirred at room temperature for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent of 4-6% MeOH in DCM to give 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)propanenitrile (0.021 g, 56.7%) as an off-white solid. MS:316.1[M+1]
[0097] Compound No. 1167: Synthesis of 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-cyclopropyl-N-(2,2,2-trifluoroethyl)acetamide [ka] Step-1: Synthesis of 2-(6-bromopyridin-3-yl)-2-cyclopropylacetonitrile: [ka] To a stirred solution of (6-bromopyridin-3-yl)(cyclopropyl)methanone (1.0 g, 0.442 mmol) in DME (12 mL) was added TosMIC (1.29 g 0.663 mmol) under inert conditions at 0° C. Then, a solution of base potassium tert-butoxide (0.991 g, 0.884 mmol) in tert-butanol (1.0 ml) was added dropwise to the reaction mixture. After addition, the mixture was stirred at room temperature for 6 hours. The progress of the reaction was monitored by TLC. After completion, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 15% ethyl acetate in hexane as the eluent to give 2-(6-bromopyridin-3-yl)-2-cyclopropylacetonitrile (0.6 g, 56.60%) as a colorless oil. MS:239[M+2]
[0098] Step-2: Synthesis of 2-(6-bromopyridin-3-yl)-2-cyclopropylacetic acid: [ka] To a stirred solution of 2-(6-bromopyridin-3-yl)-2-cyclopropylacetonitrile (0.500 g, 0.210 mmol) was added 4M HCl (5.0 mL) at room temperature. The resulting reaction mixture was stirred at 100° C. for 4 h. The reaction was monitored by TLC for completion. Upon completion, it was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over sodium sulfate, and concentrated under reduced pressure to give the pure desired product 2-(6-bromopyridin-3-yl)-2-cyclopropylacetic acid (0.320 g, 59.25%) as a sticky oil. MS:258[M+2]
[0099] Step-3: Synthesis of 2-(6-bromopyridin-3-yl)-2-cyclopropyl-N-(2,2,2-trifluoroethyl)acetamide: [ka] To a stirred solution of 2-(6-bromopyridin-3-yl)-2-cyclopropylacetic acid (0.32 g, 0.125 mmol) and azetidine-3-carbonitrile hydrochloride (0.185 g, 0.187 mmol) in DMF (3 mL) was added EDCI (0.357 g, 0.187 mmol), HOBT (0.252 g, 0.187 mmol) and DIPEA (0.322 g, 0.250 mmol). The reaction mixture was then stirred at room temperature for 12 hours. The reaction was monitored by TLC. Upon completion, the reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and evaporated under reduced pressure to give the crude product. The crude product was purified by silica gel (100-200 mesh) column chromatography; eluent was 30% ethyl acetate in hexane to give 2-(6-bromopyridin-3-yl)-2-cyclopropyl-N-(2,2,2-trifluoroethyl)acetamide (0.260 g, 61.90%) as an off-white solid. MS:339.09[M+2]
[0100] Step-4: Synthesis of 2-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-cyclopropyl-N-(2,2,2-trifluoroethyl)acetamide [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.100 g, 0.0487 mmol) and compound 2-(6-bromopyridin-3-yl)-2-cyclopropyl-N-(2,2,2-trifluoroethyl)acetamide (0.163 g, 0.0487 mmol) in dioxane (5 ml) was added K3PO4 (0.206 g, 0.0974 mmol), followed by CuI (0.018 g, 0.00974 mmol) and DMEDA (0.085 g, 0.0974 mmol). The reaction was heated at 110° C. for 6 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 4-6% MeOH in DCM to give 2-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-cyclopropyl-N-(2,2,2-trifluoroethyl)acetamide (0.130 g, 59%) as a yellow solid. MS:462.1[M+1]
[0101] Step-5: Synthesis of 2-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-cyclopropyl-N-(2,2,2-trifluoroethyl)acetamide [ka] To a stirred solution of 2-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-cyclopropyl-N-(2,2,2-trifluoroethyl)acetamide (0.080 g, 0.0173 mmol) in EtOH (7.0 mL) was added NH4Cl (2.0 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.045 g, 0.0867 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with HO:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give pure 2-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-cyclopropyl-N-(2,2,2-trifluoroethyl)acetamide (0.061 g, 82.43%) as a dark brown solid mass. MS:432.2[M+1]
[0102] Step-6: Synthesis of 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-cyclopropyl-N-(2,2,2-trifluoroethyl)acetamide: [ka] To a stirred solution of 2-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-cyclopropyl-N-(2,2,2-trifluoroethyl)acetamide (0.060 g, 0.0139 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.0046 g, 0.0027 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 7-8% MeOH in DCM to give 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-cyclopropyl-N-(2,2,2-trifluoroethyl)acetamide (0.035 g, 57.37%) as an off-white solid. MS:442.1[M+1]
[0103] Compound No. 1136: Synthesis of -7-(1-(5-(2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine [ka] Step-1: Synthesis of 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethanol [ka] To a stirred solution of 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethanone (2.5 g, 0.984 mmol) in MeOH (50 mL) was added 0.744 g (1.962 mmol) of NaBH4. oC. The reaction was allowed to stir at room temperature for 4 hours. The reaction was monitored by TLC. Upon completion, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with water, dried over Na2SO4, and evaporated under reduced pressure to give 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethanol (2.3 g, 91%) as a white solid. MS:256.2[M+1]
[0104] Step-2: Synthesis of 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethyl trifluoromethanesulfonate [ka] To a stirred solution of 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethanol (2.3 g, 0.898 mmol) in DCM (46 mL) was added DIPEA (2.31 g, 1.796 mmol) at 0° C. The resulting reaction mass was added triflic anhydride (3.7 g, 1.347 mmol) dropwise at 0° C. for 10 min and the reaction mixture was stirred at the same temperature for 4 h. The completion of the reaction was monitored by TLC. Upon completion, it was quenched with water and extracted with DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to obtain the crude reaction mass. Purification of the crude product was carried out via silica gel (100-200 mesh) column chromatography, and the desired compound was eluted with 10% acetone / n-hexane to give 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethyl trifluoromethanesulfonate (2.5 g, 72%) as a white solid. MS:388[M+1]
[0105] Step-3: Synthesis of diethyl 2-(1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethyl)malonate [ka] To a stirred solution of 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethyl trifluoromethanesulfonate (2.4 g, 0.620 mmol) in THF (50 mL) was added diethyl malonate (1.63 g, 1.240 mmol) at room temperature, which was cooled to 10° C. Base potassium tert-butoxide (1.38 g, 1.240 mmol) was added in lots at 10° C. and stirring was continued at room temperature for 6 hours. The reaction was monitored for completion by TLC. Upon completion, it was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude reaction mass. The crude product was purified via silica gel (100-200 mesh) column chromatography and the desired compound was eluted with 15% ethyl acetate / n-hexane to give diethyl 2-(1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethyl)malonate (1.6 g, 70%) as a yellow oil. MS:398.2[M+1]
[0106] Step-4: Synthesis of 2-(1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethyl)propane-1,3-diol [ka] To a stirred solution of diethyl 2-(1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethyl)malonate (1.6 g, 0.402 mmol) in EtOH (32 mL) was added NaBH4 (0.450 g, 1.206 mmol) at 0 °C. The reaction was allowed to stir at room temperature for 16 h. The reaction was monitored by TLC. Upon completion, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with water, dried over Na2SO4 and evaporated under reduced pressure to give the crude reaction mass. Purification of the crude product was carried out via silica gel (100-200 mesh) column chromatography and the desired compound was eluted with 30% acetone / n-hexane to give 2-(1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethyl)propane-1,3-diol (0.460 g, 35%) as a clear oil. MS:314[M+1]
[0107] Step-5: Synthesis of 2-bromo-5-(2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridine [ka] To a stirred solution of 2-(1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethyl)propane-1,3-diol (0.450 g, 0.143 mmol) in anhydrous THF (20 mL) was added dropwise at 0° C. under N2 at 0° C., which was stirred for 30 min. A solution of p-toluenesulfonyl chloride (0.271 g, 0.143 mmol) in anhydrous THF was added slowly. The mixture was stirred at 0° C. for 1 h, and a second batch of n-butyllithium (1.6 M in hexanes) (0.890 mL, 0.143 mmol) was added dropwise. After the addition, the mixture was heated at 60° C. and stirred for 4 h. The reaction completion was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure to obtain the crude product. Purification of the crude product was carried out via silica gel (100-200 mesh) column chromatography and the desired compound was eluted with 10% acetone / n-hexane to give 2-bromo-5-(2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridine (0.130 g, 31%) as a clear oil. MS:296.1[M+1]
[0108] Step-6: Synthesis of 4-(1-(5-(2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.088 g, 0.0429 mmol) and compound 2-bromo-5-(2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridine (0.128 g, 0.0429 mmol) in dioxane (5 ml) was added K3PO4 (0.182 g, 0.0864 mmol), followed by CuI (0.016 g, 0.00864 mmol) and DMEDA (0.076 g, 0.0864 mmol). The reaction was heated at 110° C. for 6 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 4-5% MeOH in DCM to give 4-(1-(5-(2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.085 g, 47.22%) as a yellow solid. MS:421.1[M+1]
[0109] Step-7: Synthesis of 4-(1-(5-(2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine [ka] To a stirred solution of 4-(1-(5-(2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.050 g, 0.0119 mmol) in EtOH (3.0 mL) was added NH4Cl (1.5 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.031 g, 0.0591 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with HO:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give pure 4-(1-(5-(2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.032 g, 69.56%) as a dark brown solid mass. MS:391.2[M+1]
[0110] Step-8: Synthesis of 7-(1-(5-(2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine [ka] To a stirred solution of 4-(1-(5-(2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.030 g, 0.0076 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.004 g, 0.0015 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent of 3%-5% MeOH in DCM to give 7-(1-(5-(2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (0.021 g, 70%) as an off-white solid. MS:401.0[M+1]
[0111] Compound No. 1158: Synthesis of 7-(1-(5-(1-(methylsulfonyl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine [ka] Step-1: Synthesis of 1-(6-bromopyridin-3-yl)ethanol: [ka] To a stirred solution of 1-(6-bromopyridin-3-yl)ethanone (0.5 g, 0.250 mmol) in MeOH (20 mL) was added NaBH4 (0.190 g, 0.500 mmol) at 0°C. The reaction was allowed to stir at room temperature for 4 h. The reaction was monitored by TLC. Upon completion, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with water, dried over Na2SO4 and evaporated under reduced pressure to give the crude reaction mass. Purification of the crude product was carried out via silica gel (100-200 mesh) column chromatography and the desired compound was eluted with 25% ethyl acetate / n-hexane to give 1-(6-bromopyridin-3-yl)ethanol (0.450 g, 89.10%) as a clear oil. MS:202.1[M+1]
[0112] Step-2: Synthesis of 2-bromo-5-(1-bromoethyl)pyridine [ka] To a stirred solution of 1-(6-bromopyridin-3-yl)ethanol (0.400 g, 0.198 mmol) in DCE (20 mL) was added TPP (0.778 g, 0.297 mmol) followed by carbon tetrabromide (0.932 g, 0.297 mmol) in portions at 0 °C. The resulting reaction mixture was stirred at room temperature for 6 h. The completion of the reaction was monitored by TLC. After completion, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with DCM. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 12% ethyl acetate in hexane as eluent to give 2-bromo-5-(1-bromoethyl)pyridine (0.290 g, 55.98%) as a white solid. MS:263.1[M+1]
[0113] Step-3: Synthesis of 2-bromo-5-(1-(methylsulfonyl)ethyl)pyridine: [ka] To a stirred solution of 2-bromo-5-(1-bromoethyl)pyridine (0.280 g, 0.106 mmol) in DMSO (3.0 mL) was added sodium methanesulfinate (0.163 g, 0.160 mmol). The resulting reaction mixture was added and stirred at 90° C. for 3 h. The reaction was monitored by TLC for completion. Upon completion, it was quenched with aqueous bicarbonate and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate, and concentrated under reduced pressure to give the pure desired product 2-bromo-5-(1-(methylsulfonyl)ethyl)pyridine (0.155 g, 55.35%) as a clear oil. MS:263[M+1]
[0114] Step-4: Synthesis of 4-(1-(5-(1-(methylsulfonyl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.117 g, 0.057 mmol) and compound 2-bromo-5-(1-(methylsulfonyl)ethyl)pyridine (0.150 g, 0.057 mmol) in dioxane (7 ml) was added K3PO4 (0.241 g, 0.114 mmol), followed by CuI (0.021 g, 0.0114 mmol) and DMEDA (0.100 g, 0.114 mmol). The reaction was heated at 110° C. for 6 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 5-6% MeOH in DCM to give 4-(1-(5-(1-(methylsulfonyl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.095 g, 42.79%) as a yellow solid. MS:389.1[M+1]
[0115] Step-5: Synthesis of 4-(1-(5-(1-(methylsulfonyl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine: [ka] To a stirred solution of 4-(1-(5-(1-(methylsulfonyl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.095 g, 0.024 mmol) in EtOH (7.0 mL) was added NH4Cl (2.0 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.064 g, 0.122 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with H2O:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give pure 4-(1-(5-(1-(methylsulfonyl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.060 g, 68.96%) as a dark brown solid mass. MS:359.2[M+1]
[0116] Step-6: Synthesis of 7-(1-(5-(1-(methylsulfonyl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine: [ka] To a stirred solution of 4-(1-(5-(1-(methylsulfonyl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.060 g, 0.0136 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.0046 g, 0.0027 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 7-8% MeOH in DCM to give 7-(1-(5-(1-(methylsulfonyl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (0.027 g, 44.26%) as an off-white solid. MS:369.1[M+1]
[0117] Synthesis of compound No. 1142: 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutane-1-sulfonamide [ka] Step-1: Synthesis of S-3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutylethanethioate: [ka] To a stirred solution of 2-bromo-5-(4-bromo-1,1,1-trifluorobutan-2-yl)pyridine (0.300 g, 0.086 mmol) in DMF (5 mL) was added potassium tioacetate (0.197, 0.172 mmol) under nitrogen and stirred at room temperature for 12 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with diethyl ether. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 18% ethyl acetate in hexane as eluent to give S-3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutylethanethioate (0.200 g, 68.96%) as a black solid.
[0118] Step-2: Synthesis of 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutane-1-sulfonyl chloride [ka] To a stirred solution of N-chlorosuccinamide (0.470 g, 0.350 mmol) and 2N HCl (0.5 ml) in ACN under N2 at 0° C. was added a solution of S-3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutylethanethioate (0.300 g, 0.877 mmol) in ACN dropwise. The resulting mixture was stirred at room temperature for 4 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 9-15% EA / Hexane to 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutane-1-sulfonyl chloride (0.225 g, 72.58%) as a yellow oil. MS:366[M+1]
[0119] Step-3: Synthesis of 3-(6-bromopyridin-3-yl)-4,4,4-trifluoro-N-methylbutane-1-sulfonamide [ka] To a stirred solution of 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutane-1-sulfonyl chloride (0.150 g, 0.0409 mmol) in MeOH (7 mL) was added base trimethylamine (0.124 g, 0.122 mmol). Methylamine was then added. HCl (0.082 g, 0.122 mmol) was added at room temperature. The reaction was stirred at room temperature for 4 hours. The reaction was monitored by TLC. Upon completion, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with water, dried over Na2SO4, and evaporated under reduced pressure to give pure compound 3-(6-bromopyridin-3-yl)-4,4,4-trifluoro-N-methylbutane-1-sulfonamide (0.130 g, 87.83%) as a clear oil. MS:361[M+1]
[0120] Step-4: Synthesis of 3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutane-1-sulfonamide [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.073 g, 0.036 mmol) and compound 3-(6-bromopyridin-3-yl)-4,4,4-trifluoro-N-methylbutane-1-sulfonamide (0.130 g, 0.036 mmol) in dioxane (5 ml) was added K3PO4 (0.152 g, 0.072 mmol), followed by CuI (0.013 g, 0.0072 mmol) and DMEDA (0.0066 g, 0.072 mmol). The reaction was heated at 110° C. for 6 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 6-7% MeOH in DCM to give 3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutane-1-sulfonamide (0.09 g, 45%) as a yellow solid. MS:486.1[M+1]
[0121] Step-5: Synthesis of 3-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutane-1-sulfonamide [ka] To a stirred solution of 3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutane-1-sulfonamide (0.070 g, 0.0144 mmol) in EtOH (7.0 mL) was added NH4Cl (2.0 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.40 g, 0.76 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with H2O:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give pure 3-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutane-1-sulfonamide (0.045 g, 69.23%) as a dark brown solid mass. MS:456.2[M+1]
[0122] Step-6: Synthesis of 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutane-1-sulfonamide: [ka] To a stirred solution of 3-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutane-1-sulfonamide (0.045 g, 0.0098 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.0034 g, 0.0019 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 8-9% MeOH in DCM to give 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutane-1-sulfonamide (0.021 g, 46.66%) as an off-white solid. MS:466.1[M+1]
[0123] Compound No. 1160: Synthesis of 7-(1-(5-(3-(methylsulfonyl)-1-(oxetan-3-yl)propyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine [ka]
[0124] Step-1: Synthesis of 2-bromo-5-(1-bromo-3-(methylthio)propyl)pyridine: [ka] To a stirred solution of 1-(6-bromopyridin-3-yl)-3-(methylthio)propan-1-ol (3.5 g, 1.33 mmol) in DCE (70 mL) was added TPP (4.5 g, 1.73 mmol) followed by carbon tetrabromide (5.7 g, 1.73 mmol) portionwise at 0 °C. The resulting reaction mixture was stirred at room temperature for 7 h. Completion of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with DCM. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 4% ethyl acetate in hexane as eluent to give 2-bromo-5-(1-bromo-3-(methylthio)propyl)pyridine (2.65 g, 61.05%) as a yellow oil. MS:326.1[M+1]
[0125] Step-2: Synthesis of diethyl 2-(1-(6-bromopyridin-3-yl)-3-(methylthio)propyl)malonate: [ka] To a stirred solution of 2-bromo-5-(1-bromo-3-(methylthio)propyl)pyridine (2.34 g, 0.720 mmol) in THF (50 mL) was added diethyl malonate (1.72 g, 1.08 mmol) at room temperature, which was cooled to 10° C. Basic sodium hydride (0.420 g, 1.08 mmol) was added in lots at 10° C. and stirring was continued at room temperature for 6 hours. The reaction was monitored by TLC for completion. Upon completion, it was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude reaction mass. The crude product was purified via silica gel (100-200 mesh) column chromatography and the desired compound was eluted with 15% ethyl acetate / n-hexane to give diethyl 2-(1-(6-bromopyridin-3-yl)-3-(methylthio)propyl)malonate (1.05 g, 37.5%) as a yellow oil. MS:404.2[M+1]
[0126] Step-3: Synthesis of 2-(1-(6-bromopyridin-3-yl)-3-(methylthio)propyl)propane-1,3-diol: [ka] To a stirred solution of diethyl 2-(1-(6-bromopyridin-3-yl)-3-(methylthio)propyl)malonate (1.05 g, 0.259 mmol) in EtOH (20 mL) was added NaBH4 (0.290 g, 0.777 mmol) at 0 °C. The reaction was allowed to stir at room temperature for 16 h. The reaction was monitored by TLC. Upon completion, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with water, dried over Na2SO4 and evaporated under reduced pressure to give the crude reaction mass. Purification of the crude product was carried out via silica gel (100-200 mesh) column chromatography and the desired compound was eluted with 30% acetone / n-hexane to give 2-(1-(6-bromopyridin-3-yl)-3-(methylthio)propyl)propane-1,3-diol (0.500 g, 60.16%) as a clear oil. MS:320[M+1]
[0127] Step-4: Synthesis of 2-bromo-5-(3-(methylthio)-1-(oxetan-3-yl)propyl)pyridine: [ka] To a stirred solution of 2-(1-(6-bromopyridin-3-yl)-3-(methylthio)propyl)propane-1,3-diol (0.470 g, 0.146 mmol) in anhydrous THF (30 mL) was added dropwise at 0° C. under N2 at 0° C., which was stirred for 30 min. A solution of p-toluenesulfonyl chloride (0.277 g, 0.146 mmol) in anhydrous THF was added slowly. The mixture was stirred at 0° C. for 1 h, and a second batch of n-butyllithium (1.6 M in hexanes) (0.908 mL, 0.146 mmol) was added dropwise. After addition, the mixture was heated at 60° C. and stirred for 4 h. The reaction completion was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure to obtain the crude product. Purification of the crude product was carried out via silica gel (100-200 mesh) column chromatography and the desired compound was eluted with 11% acetone / n-hexane to give 2-bromo-5-(3-(methylthio)-1-(oxetan-3-yl)propyl)pyridine (0.160 g, 36.1%) as a clear oil. MS:302.1[M+1]
[0128] Step-5: Synthesis of 2-bromo-5-(3-(methylsulfonyl)-1-(oxetan-3-yl)propyl)pyridine: [ka] To a stirred solution of 2-bromo-5-(3-(methylthio)-1-(oxetan-3-yl)propyl)pyridine (0.160 g, 0.0520 mmol) in acetone:H2O (20 mL, 7:3) under nitrogen at 0° C., oxone (0.487 g, 0.158 mmol) was added and stirred at the same temperature for 12 h. The reaction progress was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 3% MeOH in DCM as the eluent to give 2-bromo-5-(3-(methylsulfonyl)-1-(oxetan-3-yl)propyl)pyridine (0.130 g, 73.86%) as a colorless oil. MS:334.0[M+1]
[0129] Step-6: Synthesis of 4-(1-(5-(3-(methylsulfonyl)-1-(oxetan-3-yl)propyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine: [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.079 g, 0.0389 mmol) and compound 2-bromo-5-(3-(methylsulfonyl)-1-(oxetan-3-yl)propyl)pyridine (0.130 g, 0.0389 mmol) in dioxane (5 ml) was added K3PO4 (0.164 g, 0.0778 mmol), followed by CuI (0.014 g, 0.0077 mmol) and DMEDA (0.068 g, 0.0778 mmol). The reaction was heated at 110° C. for 6 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 4-5% MeOH in DCM to give 4-(1-(5-(3-(methylsulfonyl)-1-(oxetan-3-yl)propyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.085 g, 47.22%) as a yellow solid. MS:459.1[M+1]
[0130] Step-7: Synthesis of 4-(1-(5-(3-(methylsulfonyl)-1-(oxetan-3-yl)propyl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine [ka] To a stirred solution of 4-(1-(5-(3-(methylsulfonyl)-1-(oxetan-3-yl)propyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.060 g, 0.0131 mmol) in EtOH (7.0 mL) was added NH4Cl (2.0 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.034 g, 0.06591 mmol) was added and stirred at 70 °C for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with H2O:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give pure 4-(1-(5-(3-(methylsulfonyl)-1-(oxetan-3-yl)propyl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.045 g, 80.35%) as a dark brown solid mass. MS:429.2[M+1]
[0131] Step-8: Synthesis of 7-(1-(5-(3-(methylsulfonyl)-1-(oxetan-3-yl)propyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine: [ka] To a stirred solution of 4-(1-(5-(3-(methylsulfonyl)-1-(oxetan-3-yl)propyl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.045 g, 0.0105 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.0036 g, 0.0021 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 6-7% MeOH in DCM to give 7-(1-(5-(3-(methylsulfonyl)-1-(oxetan-3-yl)propyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (0.025 g, 54%) as an off-white solid. MS:439.0[M+1]
[0132] Compound No. 1175: Synthesis of 7-(1-(6-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine [ka] Step-1: Synthesis of 1-(6-bromopyridin-2-yl)-2,2,2-trifluoroethanone: [ka] To a stirred solution of 2,6-dibromopyridine (5.0 g, 2.12 mmol) in THF (50 mL) was added n-butyllithium (2.5 M in hexane) (12.5 mL, 3.18 mmol) under nitrogen at −78° C. and stirred at the same temperature for 1 h. Then 2,2,2-trifluoro-1-morpholinoethanone (5.06 g, 2.76 mmol) was added dropwise to the reaction mixture and stirred at −78° C. for 1 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with diethyl ether. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 18% ethyl acetate in hexane as the eluent to give 1-(6-bromopyridin-2-yl)-2,2,2-trifluoroethanone (3.5 g, 64.81%) as a colorless oil.
[0133] Step-2: Synthesis of (E / Z)-ethyl 3-(6-bromopyridin-2-yl)-4,4,4-trifluorobut-2-enoate [ka] To a stirred solution of triethylphosphonoacetate (3.9 g, 1.77 mmol) and THF (60 ml) at 0° C. under N2, base potassium tert-butoxide (1.98 g, 1.77 mmol) was added lot by lot. The resulting mixture was stirred at room temperature for 1 h for anion generation. A solution of 1-(6-bromopyridin-2-yl)-2,2,2-trifluoroethanone (3.0 g, 1.18 mmol) in THF (15 ml) was added slowly. After addition, the mixture was stirred at room temperature for 6 h. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 9-15% EA / hexane to give (E / Z)-ethyl 3-(6-bromopyridin-2-yl)-4,4,4-trifluorobut-2-enoate (1.5 g, 40%) as a yellow oil. MS:324[M+1]
[0134] Step-3: Synthesis of 3-(6-bromopyridin-2-yl)-4,4,4-trifluorobutan-1-ol: [ka] To a stirred solution of (E / Z)-ethyl 3-(6-bromopyridin-2-yl)-4,4,4-trifluorobut-2-enoate (1.5 g, 462 mmol) in EtOH (30 mL) was added NaBH4 (0.520 g, 1380 mmol) at 0°C. The reaction was allowed to stir at room temperature for 14 h. The reaction was monitored by TLC. Upon completion, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with water, dried over Na2SO4 and evaporated under reduced pressure to give the crude reaction mass. Purification of the crude product was carried out via silica gel (100-200 mesh) column chromatography and the desired compound was eluted with 30% ethyl acetate / n-hexane to give 3-(6-bromopyridin-2-yl)-4,4,4-trifluorobutan-1-ol (0.610 g, 46.5%) as a clear oil. MS:284[M+1]
[0135] Step-4: Synthesis of 3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-2-yl)-4,4,4-trifluorobutan-1-ol [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.253 g, 123 mmol) and compound 3-(6-bromopyridin-2-yl)-4,4,4-trifluorobutan-1-ol (0.350 g, 123 mmol) in dioxane (5 ml) was added K3PO4 (0.521 g, 246 mmol), followed by CuI (0.046 g, 0.246 mmol) and DMEDA (0.216 g, 246 mmol). The reaction was heated at 110° C. for 6 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 6-7% MeOH in DCM to give 3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-2-yl)-4,4,4-trifluorobutan-1-ol (0.250 g, 50%) as a yellow solid. MS:409.1[M+1]
[0136] Step-5: Synthesis of 4-(1-(6-(4-bromo-1,1,1-trifluorobutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine [ka] To a stirred solution of 3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-2-yl)-4,4,4-trifluorobutan-1-ol (0.120 g, 0.29 mmol) in DCE (10 mL) was added TPP (0.115 g, 0.44 mmol) followed by portionwise addition of carbon tetrabromide (0.145 g, 0.44 mmol) at 0° C. The resulting reaction mixture was stirred at room temperature for 7 hours. The completion of the reaction was monitored by TLC. After completion, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with DCM. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 2-3% methanol in DCMA as the eluent to give 4-(1-(6-(4-bromo-1,1,1-trifluorobutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.065 g, 47.05%) as a yellow solid. MS:471.1[M+1]
[0137] Step-6: Synthesis of 4-(1-(6-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine: [ka] To a stirred solution of 4-(1-(6-(4-bromo-1,1,1-trifluorobutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.065 g, 0.130 mmol) in DMSO (3.0 mL) was added sodium methanesulfinate (0.027 g, 0.20 mmol). The resulting reaction mixture was added and stirred at 90° C. for 3 hours. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 6-7% MeOH / DCM to give 4-(1-(6-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.052 g, 81.20%) as a yellow solid. MS:471[M+1]
[0138] Step-7: Synthesis of 4-(1-(6-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine: [ka] To a stirred solution of 4-(1-(6-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.052 g, 0.11 mmol) in EtOH (7.0 mL) was added NH4Cl (2.0 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.029 g, 0.55 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with HO:EtOAc (50 mL, 5:5) and passed through Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give pure 4-(1-(6-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.036 g, 75%) as a dark brown solid mass. MS:441.2[M+1]
[0139] Step-8: Synthesis of 7-(1-(6-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine: [ka] To a stirred solution of 4-(1-(6-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.035 g, 0.079 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.0027 g, 0.015 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 8-9% MeOH in DCM to give 7-(1-(6-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (0.021 g, 60%) as an off-white solid. MS:451.1[M+1]
[0140] Compound No. 1176: Synthesis of 7-(1-(4-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine [ka]
[0141] Step-1: Synthesis of 1-(2-bromopyridin-4-yl)-2,2,2-trifluoroethanone: [ka] To a stirred solution of 2,4-dibromopyridine (5.0 g, 2.12 mmol) in THF (50 mL) was added n-butyllithium (2.5 M in hexane) (12.5 mL, 3.18 mmol) under nitrogen at −78° C. and stirred at the same temperature for 1 h. Then 2,2,2-trifluoro-1-morpholinoethanone (5.06 g, 2.76 mmol) was added dropwise to the reaction mixture and stirred at −78° C. for 1 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with diethyl ether. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 18% ethyl acetate in hexane as the eluent to give 1-(2-bromopyridin-4-yl)-2,2,2-trifluoroethanone (3.5 g, 64.81%) as a colorless oil.
[0142] Step-2: Synthesis of (E / Z)-ethyl 3-(2-bromopyridin-4-yl)-4,4,4-trifluorobut-2-enoate [ka] To a stirred solution of triethylphosphonoacetate (3.9 g, 1.77 mmol) and THF (60 ml) under N2 at 0° C. was added base potassium tert-butoxide (1.98 g, 1.77 mmol) in lots. The resulting mixture was stirred at room temperature for 1 h for anion generation. A solution of 1-(2-bromopyridin-4-yl)-2,2,2-trifluoroethanone (3.0 g, 1.18 mmol) in THF (15 ml) was added slowly. After addition, the mixture was stirred at room temperature for 6 h. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 9-15% EA / hexane to give (E / Z)-ethyl 3-(2-bromopyridin-4-yl)-4,4,4-trifluorobut-2-enoate (1.5 g, 40%) as a yellow oil. MS:324[M+1]
[0143] Step-3: Synthesis of 3-(2-bromopyridin-4-yl)-4,4,4-trifluorobutan-1-ol: [ka] To a stirred solution of (E / Z)-ethyl 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobut-2-enoate (1.5 g, 462 mmol) in EtOH (30 mL) was added NaBH4 (0.520 g, 1380 mmol) at 0°C. The reaction was allowed to stir at room temperature for 14 h. The reaction was monitored by TLC. Upon completion, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with water, dried over Na2SO4 and evaporated under reduced pressure to give the crude reaction mass. Purification of the crude product was carried out via silica gel (100-200 mesh) column chromatography and the desired compound was eluted with 30% ethyl acetate / n-hexane to give 3-(2-bromopyridin-4-yl)-4,4,4-trifluorobutan-1-ol (0.610 g, 46.5%) as a clear oil. MS:284[M+1]
[0144] Step-4: Synthesis of 3-(2-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-4-yl)-4,4,4-trifluorobutan-1-ol [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.253 g, 123 mmol) and compound 3-(2-bromopyridin-4-yl)-4,4,4-trifluorobutan-1-ol (0.350 g, 123 mmol) in dioxane (5 ml) was added K3PO4 (0.521 g, 246 mmol), followed by CuI (0.046 g, 0.246 mmol) and DMEDA (0.216 g, 246 mmol). The reaction was heated at 110° C. for 6 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 6-7% MeOH in DCM to give 3-(2-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-4-yl)-4,4,4-trifluorobutan-1-ol (0.250 g, 50%) as a yellow solid. MS:409.1[M+1]
[0145] Step-5: Synthesis of 4-(1-(4-(4-bromo-1,1,1-trifluorobutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine [ka] To a stirred solution of 3-(2-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-4-yl)-4,4,4-trifluorobutan-1-ol (0.120 g, 0.29 mmol) in DCE (10 mL) was added TPP (0.115 g, 0.44 mmol) followed by portionwise addition of carbon tetrabromide (0.145 g, 0.44 mmol) at 0° C. The resulting reaction mixture was stirred at room temperature for 7 hours. The completion of the reaction was monitored by TLC. After completion, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with DCM. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 2-3% methanol in DCMA as the eluent to give 4-(1-(4-(4-bromo-1,1,1-trifluorobutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.065 g, 47.05%) as a yellow solid. MS:471.1[M+1]
[0146] Step-6: Synthesis of 4-(1-(4-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine: [ka] To a stirred solution of 4-(1-(4-(4-bromo-1,1,1-trifluorobutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.065 g, 0.130 mmol) in DMSO (3.0 mL) was added sodium methanesulfinate (0.027 g, 0.20 mmol). The resulting reaction mixture was added and stirred at 90° C. for 3 hours. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 6-7% MeOH / DCM to give 4-(1-(4-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.052 g, 81.20%) as a yellow solid. MS:471[M+1]
[0147] Step-7: Synthesis of 4-(1-(4-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine: [ka] To a stirred solution of 4-(1-(4-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.052 g, 0.11 mmol) in EtOH (7.0 mL) was added NH4Cl (2.0 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.029 g, 0.55 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with HO:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give pure 4-(1-(4-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.036 g, 75%) as a dark brown solid mass. MS:441.2[M+1]
[0148] Step-8: Synthesis of 7-(1-(4-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine: [ka] To a stirred solution of 4-(1-(5-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.035 g, 0.079 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.0027 g, 0.015 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and diluted with 10% MeO in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent: 8-9% MeOH in DCM to give 7-(1-(4-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (0.021 g, 60%) as an off-white solid. MS:451.1[M+1]
[0149] Compound No. 1178: Synthesis of 1-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethyl)-3-cyclopropylurea [ka] Step-1: Synthesis of 4-nitrophenyl cyclopropyl carbamate: [ka] To a stirred solution of cyclopropanamine (2.0 g, 3.508 mmol) in DCM (60.0 mL) was added trimethylamine (5.3 g, 5.26 mmol) followed by 4-nitrophenyl chloroformate (9.1 g, 4.55 mmol) at 0° C. The resulting reaction mixture was stirred at room temperature for 6 h. The reaction completion was monitored by TLC. Upon completion, the solid extract was directly filtered onto a Buckner and then washed with DCM to give the pure product (1.2 g, 15.58%) as a white solid. MS:223[M+1]
[0150] Step-2: Synthesis of 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethanamine [ka] To a stirred solution of 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethyl trifluoromethanesulfonate (0.650 g, 0.167 mmol) in DMF (5 ml) was added sodium azide (0.108 g, 0.167 mmol) at room temperature. The reaction mixture was stirred at the same temperature for 6 hours. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to obtain the pure intermediate. To a solution of the azide intermediate (0.550 g, 0.192 mmol) was added TPP (0.512 g, 0.192 mmol) in THF:H2O (8:2 ml) at room temperature and then stirring was continued at 60° C. for 12 hours. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 20-30% acetone in hexane to give 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethanamine (0.160 g, 32%) as a yellow oil. MS:255.1[M+1]
[0151] Step-3: Synthesis of 1-(1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethyl)-3-cyclopropylurea [ka] To a stirred solution of 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethanamine (0.200 g, 0.078 mmol) in THF (10.0 mL) was added potassium carbonate (0.107 g, 0.078 mmol) followed by 4-nitrophenylcyclopropylcarbamate (0.248 g, 0.011 mmol). The resulting reaction mixture was stirred at 60° C. for 6 h. The reaction was monitored by TLC for completion. Upon completion, it was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 15-20% acetone / hexane to give (0.120 g, 50.84%) as a white solid. MS:338[M+1]
[0152] Step-4: Synthesis of 1-(1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethyl)-3-cyclopropylurea [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.090 g, 0.0443 mmol) and compound 1-(1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethyl)-3-cyclopropylurea (0.150 g, 0.0443 mmol) in dioxane (5 ml) was added K3PO4 (0.122 g, 0.0886 mmol), followed by CuI (0.016 g, 0.00886 mmol) and DMEDA (0.077 g, 0.0886 mmol). The reaction was heated at 110° C. for 6 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 9-10% MeOH in DCM to give 1-(1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethyl)-3-cyclopropylurea (0.090 g, 45%) as a yellow solid. MS:463.1[M+1]
[0153] Step-5: Synthesis of 1-(1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethyl)-3-cyclopropylurea [ka] To a stirred solution of 1-(1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethyl)-3-cyclopropylurea (0.085 g, 0.0183 mmol) in EtOH (7.0 mL) was added NH4Cl (2.0 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.048 g, 0.0919 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with HO:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give pure 1-(1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethyl)-3-cyclopropylurea (0.045 g, 56.96%) as a dark brown solid mass. MS:433.2[M+1]
[0154] Step-6: Synthesis of 1-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethyl)-3-cyclopropylurea: [ka] To a stirred solution of 1-(1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethyl)-3-cyclopropylurea (0.045 g, 0.0104 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.0035 g, 0.0020 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and eluted with 10% MeO in DCM. H. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent: 10-11% MeOH in DCM to give 1-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethyl)-3-cyclopropylurea (0.023 g, 51%) as an off-white solid. MS:443.1[M+1]
[0155] Compound No. 1179: Synthesis of 1-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)-3-cyclopropylurea [ka] Step-1: Synthesis of 1-(3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutyl)-3-cyclopropylurea: [ka] To a stirred solution of 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutan-1-amine (0.130 g, 0.045 mmol) in ACN (10.0 mL) was added trimethylamine (0.136 g, 0.135 mmol) followed by 4-nitrophenylcyclopropylcarbamate (0.152 g, 0.068 mmol). The resulting reaction mixture was stirred at 60° C. for 6 h. The reaction was monitored by TLC for completion. Upon completion, it was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 25-30% acetone / hexane to give (0.140 g, 83.83%) as a sticky oil. MS:367[M+2]
[0156] Step-2: Synthesis of 1-(3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)-3-cyclopropylurea [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.073 g, 0.0356 mmol) and compound 1-(3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutyl)-3-cyclopropylurea (0.130 g, 0.0356 mmol) in dioxane (5 ml) was added K3PO4 (0.150 g, 0.0712 mmol), followed by CuI (0.013 g, 0.00712 mmol) and DMEDA (0.062 g, 0.0712 mmol). The reaction was heated at 110° C. for 6 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 7-8% MeOH in DCM to give 1-(3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)-3-cyclopropylurea (0.080 g, 45.97%) as a yellow solid. MS:491.1[M+1]
[0157] Step-3: Synthesis of 1-(3-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)-3-cyclopropylurea [ka] To a stirred solution of 1-(3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)-3-cyclopropylurea (0.060 g, 0.0122 mmol) in EtOH (7.0 mL) was added NH4Cl (2.0 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.032 g, 0.0612 mmol) was added and stirred at 70 °C for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with H2O:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give pure 1-(3-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)-3-cyclopropylurea (0.042 g, 75%) as a dark brown solid mass. MS:461.2[M+1]
[0158] Step-4: Synthesis of 1-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)-3-cyclopropylurea: [ka] To a stirred solution of 1-(3-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)-3-cyclopropylurea (0.042 g, 0.0091 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.0031 g, 0.0018 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent: 8-9% MeOH in DCM to give 1-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)-3-cyclopropylurea (0.021 g, 48.83%) as an off-white solid. MS:471.1[M+1]
[0159] Compound No. 1075: Synthesis of 2-(2-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)oxazol-4-yl)acetonitrile [ka] Step-1: Synthesis of ethyl 2-aminooxazole-4-carboxylate [ka] To a stirred solution of ethyl 3-bromo-2-oxopropanoate (1.0 g, 5.128 mmol) in ethanol (20 mL) was added urea (0.462 g, 7.692 mmol) at room temperature. The resulting reaction mixture was stirred at reflux temperature overnight. Completion of the reaction was monitored by TLC. Upon completion, it was quenched with ice water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to obtain the crude reaction mass. Purification of the crude product was carried out via silica gel (100-200 mesh) column chromatography to obtain the desired compound, eluted with 40% ethyl acetate / n-hexane (Heaxane) to give ethyl 2-aminooxazole-4-carboxylate (0.700 g, 87.5%) as a cream colored solid. MS:157.2[M+1]
[0160] Step-2: Synthesis of ethyl 2-chlorooxazole-4-carboxylate: [ka] To a stirred solution of CuCl2 (1.29 g, 9.609 mmol) in ACN (20 mL) was added tert-butylnitrile (0.991 g, 9.609 mmol) at room temperature. The resulting reaction mass was heated at 65 °C. Compound ethyl 2-aminooxazole-4-carboxylate (1.0 g, 6.406 mmol) was added in portions at 65 °C and stirring was continued for 2 h. Completion of the reaction was monitored by TLC. The reaction mixture was cooled to 0 °C, acidified with 6N HCl and extracted with ether. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to obtain the crude reaction mass. Purification of the crude product was carried out via silica gel (100-200 mesh) column chromatography and the desired compound was eluted with 18% ethyl acetate / n-hexane to give ethyl 2-chlorooxazole-4-carboxylate (0.500 g, 44.6%) as a brown solid. MS:176[M+1]
[0161] Step-3: Synthesis of (2-chlorooxazol-4-yl)methanol [ka] A stirred solution of ethyl 2-chlorooxazole-4-carboxylate (0.400 g, 2.271 mmol) in DCM (10 mL) was cooled to -78°C under inert conditions. DIBAL-H (3.4 ml, 3.410 mmol) was added at -78°C and stirring was continued at the same temperature for 1 h. It was then stirred at room temperature for 16 h. Completion of the reaction was monitored by TLC. The reaction mixture was quenched with crushed ice followed by 1N HCl and extracted with ether. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude product (2-chlorooxazol-4-yl)methanol (0.250 g, 82.5%) as a yellow liquid, which was used as such in the next step. MS:134.1[M+1]
[0162] Step-4: Synthesis of (2-chlorooxazol-4-yl)methyl methanesulfonate [ka] To a stirred solution of (2-chlorooxazol-4-yl)methanol (0.10 g, 0.749 mmol) in DCM (10 mL) was added base triethylamine (0.114 g, 1.123 mmol) at room temperature, which was cooled to 0° C. Mesyl chloride (0.103 g, 0.898 mmol) was added dropwise at 0° C. and stirring was continued for 6 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with water and extracted with DCM. The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure to give pure (2-chlorooxazol-4-yl)methyl methanesulfonate (0.155 g, 97.77%) as an off-white solid. MS:211.1[M+1]
[0163] Step-5: Synthesis of 2-(2-chlorooxazol-4-yl)acetonitrile [ka] To a stirred solution of (2-chlorooxazol-4-yl)methyl methanesulfonate (0.500 g, 2.362 mmol) in ACN (10 mL) was added TBAF 1M in THF (4.72 ml, 4.725 mmol) at room temperature followed by TMSCN (0.469 g, 4.725 mmol). The resulting reaction mixture was stirred at room temperature for 6 h. Completion of the reaction was monitored by TLC. Upon completion, it was quenched with water, extracted with ethyl acetate, dried over sodium sulfate and concentrated under reduced pressure to give the crude reaction mass. Purification of the crude product was carried out via silica gel (100-200 mesh) column chromatography and the desired compound was eluted with 18% ethyl acetate / n-hexane to give pure 2-(2-chlorooxazol-4-yl)acetonitrile (0.210 g, 62.31%) as a white solid. MS:143.2[M+1]
[0164] Step-6: Synthesis of 2-(2-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)oxazol-4-yl)acetonitrile [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.040 g, 0.195 mmol) was added DMF (4 ml), potassium tert-butoxide (0.022 g, 0.195 mmol) and compound 2-(2-chlorooxazol-4-yl)acetonitrile (0.028 g, 0.39 mmol) at room temperature. The reaction was heated at 80° C. for 12 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 5-6% MeOH in DCM to give 2-(2-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)oxazol-4-yl)acetonitrile (0.030 g, 49.45%) as a yellow solid. MS:312.1[M+1]
[0165] Step-7: Synthesis of 2-(2-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)oxazol-4-yl)acetonitrile [ka] To a stirred solution of 2-(2-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)oxazol-4-yl)acetonitrile (0.030 g, 0.096 mmol) in EtOH (3.0 mL) was added NH4Cl (2.5 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.017 g, 0.48 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with HO:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give 2-(2-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)oxazol-4-yl)acetonitrile (0.025 g, 92%) as a dark brown solid mass. MS:283.2[M+1]
[0166] Step-8: Synthesis of 2-(2-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)oxazol-4-yl)acetonitrile [ka] To a stirred solution of 2-(2-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)oxazol-4-yl)acetonitrile (0.025 g, 0.088 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.003 g, 0.0017 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent of 6-7% MeOH in DCM to give 2-(2-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)oxazol-4-yl)acetonitrile (0.011 g, 44%) as an off-white solid. MS:293.1[M+1]
[0167] Compound No. 1078: Synthesis of 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)acetonitrile [ka]
[0168] Step-1: Synthesis of (6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)methanol: [ka] To a stirred solution of 6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridine-3-carbaldehyde (0.50 g, 1.612 mmol) in methanol / THF (10 mL, 1:1) was added sodium borohydride (0.069 g, 1.612 mmol) at 0° C. and the mixture was stirred at room temperature for 3 h. The reaction progress was monitored by TLC. After completion of the reaction, water (10 mL) was added to the reaction mixture and the product was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated under reduced pressure to give (6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)methanol (0.5 g, 100%) as a yellow solid. MS:313.28[M+1]
[0169] Step-2: Synthesis of (6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)methyl methanesulfonate [ka] To a stirred solution of (6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)methanol (0.15 g, 0.480 mmol) in DCM (5.0 mL) was added MsCl (0.06 g, 0.528 mmol) at 0° C. under nitrogen. To the resulting reaction mixture was added dropwise a solution of TEA (0.063 g, 0.629 mmol) in DCM (1.0 mL) and stirred at 0° C. for 15 min, then warmed to room temperature and the progress of the reaction was monitored by TLC. Upon completion, it was quenched with water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated under reduced pressure to give (6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)methyl methanesulfonate (0.19 g, 100%) as a crude yellow oily mass. MS:391.37[M+1]
[0170] Step-3: Synthesis of 2-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)acetonitrile [ka] To a stirred solution of (6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)methyl methanesulfonate (0.25 g, 0.641 mmol) in ACN (5 mL) under nitrogen at 0° C. was added TMSCN (0.13 g, 1.282 mmol), followed by TBAF (1 M solution in THF, 1.3 mL, 1.282 mmol) and the resulting solution was heated at 50° C. overnight. The reaction progress was monitored by TLC. After completion of the reaction, the reaction mass was cooled to 0° C. and quenched with 1 M HCl. The product was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 1% MeOH / DCM as the eluent to give 2-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)acetonitrile (0.08 g, 40%) as a yellow oil. MS:322.29[M+1]
[0171] Step-4: Synthesis of 2-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)acetonitrile [ka] A stirred solution of 2-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)acetonitrile (0.05 g, 0.1557 mmol) in methanol (5 mL) was hydrogenated over 10% Pd / C (0.005 g, 10% w / w) using a hydrogen balloon. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was filtered through Celite and the filtrate was evaporated under reduced pressure to give 2-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)acetonitrile (0.044 g, 99%) as a brown solid. MS:292.31[M+1]
[0172] Step-5: Synthesis of 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)acetonitrile [ka] To a stirred solution of 2-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)acetonitrile (0.045 g, 0.1512 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.0 mL). To the resulting reaction mixture was added PTSA (0.005 g, 0.0302 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous sodium bicarbonate and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent of 3%-5% MeOH in DCM to give 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)acetonitrile (0.05 g, 10%) as an off-white solid. MS:302.31[M+1]
[0173] Compound No. 1094: Synthesis of N-(2,2,2-trifluoroethyl)-4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide [ka]
[0174] Step-1: Synthesis of N-(2,2,2-trifluoroethyl)-4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide: [ka] To a stirred solution of tert-butyl 2-phenyl-7-(1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine hydrochloride (0.015 g, 0.05042 mmol) and 4-nitrophenyl 2,2,2-trifluoroethylcarbamate (0.013 g, 0.05042 mmol) in anhydrous ACN (3 mL), triethylamine (0.01 g, 0.1008 mmol) was added and stirred at room temperature overnight. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 2% methanol in DCM as the eluent to yield N-(2,2,2-trifluoroethyl)-4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide (0.004 g, 20%) as a white solid. MS:387.33[M+1]
[0175] Compound No. 1180: Synthesis of 3-cyclopentyl-3-(4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)propanenitrile [ka] Step-1: Synthesis of tert-butyl 4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazole-1-carboxylate: [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (1 g, 4.878 mmol) in DCM (10 mL) was added TEA (2.0 mL, 14.634 mmol) dropwise at room temperature and the reaction was allowed to stir for 15 minutes. After 15 minutes, Boc anhydride (1.59 g, 7.317 mmol) was added to it and stirred for 6 hours. The reaction was monitored by TLC. Upon completion, the reaction was quenched with water and extracted with DCM. The organic layer was washed with water, NaHCO3, brine, dried over Na2SO4 and evaporated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography: eluent of 1% MeOH in DCM to give tert-butyl 4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazole-1-carboxylate (1.2 g, 81.0%) as a yellow solid. MS:306.29[M+1]
[0176] Step-2: Synthesis of tert-butyl 4-(2,3-diaminopyridin-4-yl)-1H-pyrazole-1-carboxylate: [ka] A stirred solution of tert-butyl 4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazole-1-carboxylate (0.5 g, 1.639 mmol) in methanol (5 mL) was hydrogenated over 10% Pd / C (0.05 g, 10% w / w) using a hydrogen balloon. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was filtered through Celite and the filtrate was evaporated under reduced pressure to give tert-butyl 4-(2,3-diaminopyridin-4-yl)-1H-pyrazole-1-carboxylate (0.45 g, 99.8%) as a brown solid. MS:276.31[M+1]
[0177] Step-3: Synthesis of tert-butyl 4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxylate: [ka] To a stirred solution of tert-butyl 4-(2,3-diaminopyridin-4-yl)-1H-pyrazole-1-carboxylate (0.4 g, 1.452 mmol) and benzaldehyde (0.15 g, 1.452 mmol) in DCE (5 mL) was added AcOH (0.4 mL) at 0° C. and stirred for 30 min. Then sodium triacetoxyborohydride (0.13 g, 2.179 mmol) was added and the resulting mixture was heated at 60° C. overnight. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was cooled to 0° C. and quenched with ice water. The product was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 1% MeOH / DCM as the eluent to give tert-butyl 4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxylate (0.3 g, 57.1%) as a white solid. MS:362.4[M+1]
[0178] Step-4: Synthesis of tert-butyl 2-phenyl-7-(1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine hydrochloride: [ka] To tert-butyl 4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxylate (0.3 g, 0.831 mmol), 4M HCl in dioxane (3 mL) was added and stirred at room temperature for 3 hours. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was concentrated under reduced pressure, washed with diethyl ether and dried to obtain tert-butyl 2-phenyl-7-(1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine hydrochloride (0.25 g, 100%) as a white solid. MS:298.4[M+1]
[0179] Step-5: Synthesis of 3-cyclopentyl-3-(4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)propanenitrile: [ka] To a stirred solution of tert-butyl 2-phenyl-7-(1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine hydrochloride (0.03 g, 0.115 mmol) and 3-cyclopentylacrylonitrile (0.015 g, 0.126 mmol) in anhydrous ACN (5 mL) was added DBU (0.052 g, 0.3448 mmol) and heated at 90° C. overnight. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 3% methanol in DCM as the eluent to give 3-cyclopentyl-3-(4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)propanenitrile (0.005 g, 11.3%) as a white solid. MS:383.46[M+1]
[0180] Compound No. 1174: Synthesis of 7-(1-(6-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine [ka]
[0181] Step-1: Synthesis of (E / Z)-ethyl 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobut-2-enoate [ka] To a stirred solution of triethylphosphonoacetate (3.9 g, 1.77 mmol) and THF (60 ml) under N2 at 0° C. was added base potassium tert-butoxide (1.98 g, 1.77 mmol) in lots. The resulting mixture was stirred at room temperature for 1 h for anion generation. A solution of 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethanone (3.0 g, 1.18 mmol) in THF (15 ml) was added slowly. After addition, the mixture was stirred at room temperature for 6 h. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 9-15% EA / hexane to give (E / Z)-ethyl 3-(6-bromopyridin-2-yl)-4,4,4-trifluorobut-2-enoate (1.5 g, 40%) as a yellow oil. MS:324[M+1]
[0182] Step-2: Synthesis of 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutan-1-ol: [ka] To a stirred solution of (E / Z)-ethyl 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobut-2-enoate (1.5 g, 462 mmol) in EtOH (30 mL) was added NaBH4 (0.520 g, 1380 mmol) at 0°C. The reaction was allowed to stir at room temperature for 14 h. The reaction was monitored by TLC. Upon completion, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with water, dried over Na2SO4 and evaporated under reduced pressure to give the crude reaction mass. Purification of the crude product was carried out via silica gel (100-200 mesh) column chromatography and the desired compound was eluted with 30% ethyl acetate / n-hexane to give 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutan-1-ol (0.610 g, 46.5%) as a clear oil. MS:284[M+1]
[0183] Step-3: Synthesis of 3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutan-1-ol [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.253 g, 123 mmol) and compound 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutan-1-ol (0.350 g, 123 mmol) in dioxane (5 ml) was added K3PO4 (0.521 g, 246 mmol), followed by CuI (0.046 g, 0.246 mmol) and DMEDA (0.216 g, 246 mmol). The reaction was heated at 110° C. for 6 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 6-7% MeOH in DCM to give 3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutan-1-ol (0.250 g, 50%) as a yellow solid. MS:409.1[M+1]
[0184] Step-4: Synthesis of 4-(1-(5-(4-bromo-1,1,1-trifluorobutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine [ka] To a stirred solution of 3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutan-1-ol (0.120 g, 0.29 mmol) in DCE (10 mL) was added TPP (0.115 g, 0.44 mmol) followed by portionwise addition of carbon tetrabromide (0.145 g, 0.44 mmol) at 0° C. The resulting reaction mixture was stirred at room temperature for 7 hours. The completion of the reaction was monitored by TLC. After completion, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with DCM. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 2-3% methanol in DCMA as the eluent to give 4-(1-(5-(4-bromo-1,1,1-trifluorobutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.065 g, 47.05%) as a yellow solid. MS:471.1[M+1]
[0185] Step-5: Synthesis of 4-(1-(5-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine: [ka] To a stirred solution of 4-(1-(5-(4-bromo-1,1,1-trifluorobutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.065 g, 0.130 mmol) in DMSO (3.0 mL) was added sodium methanesulfinate (0.027 g, 0.20 mmol). The resulting reaction mixture was added and stirred at 90° C. for 3 hours. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 6-7% MeOH / DCM to give 4-(1-(5-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.052 g, 81.20%) as a yellow solid. MS:471[M+1]
[0186] Step-6: Synthesis of 4-(1-(5-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine: [ka] To a stirred solution of 4-(1-(5-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3-nitropyridin-2-amine (0.052 g, 0.11 mmol) in EtOH (7.0 mL) was added NH4Cl (2.0 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.029 g, 0.55 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with HO:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give pure 4-(1-(5-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.036 g, 75%) as a dark brown solid mass. MS:441.2[M+1]
[0187] Step-7: Synthesis of 7-(1-(5-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine: [ka] To a stirred solution of 4-(1-(5-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.035 g, 0.079 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.0027 g, 0.015 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 8-9% MeOH in DCM to give 7-(1-(5-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (0.021 g, 60%) as an off-white solid. MS:451.1[M+1]
[0188] Compound No. 1157: Synthesis of 2-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)acetonitrile [ka]
[0189] Step-1: Synthesis of 1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethanol [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.500 g, 2.439 mmol) and compound 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethanol (0.68 g, 2.682 mmol) in DMSO (5 ml) was added K2CO3 (1.0 g, 7.317 mmol), followed by CuI (0.045 g, 0.243 mmol) and s-proline (0.146 g, 1.219 mmol). The reaction was heated at 110° C. for 16 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 2-3% MeOH in DCM to give 1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethanol (0.35 g, 37.8%) as a yellow solid. MS:381.28[M+1]
[0190] Step-2: Synthesis of 2-(1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)acetonitrile [ka] To a stirred solution of 1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethanol (0.3 g, 0.7894 mmol) in DMF (10 mL) was added NaH (0.31 g, 0.7894 mmol) under nitrogen at 0° C. and stirred at the same temperature for 30 min. To the resulting reaction mass was added 2-bromoacetonitrile (0.094 g, 0.7894 mmol) and stirred at room temperature for 4 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 1% methanol in DCM as the eluent to give 2-(1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)acetonitrile (0.14 g, 42.4%) as a yellow solid. MS:420.32[M+1]
[0191] Step-3: Synthesis of 2-(1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)acetonitrile [ka] To a stirred solution of 2-(1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)acetonitrile (0.050 g, 0.119 mmol) in EtOH (10 mL) was added NH4Cl (2.5 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.033 g, 0.59 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with HO:EtOAc (50 mL, 5:5) and filtered through Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give pure 2-(1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)acetonitrile (0.040 g, 86.9%) as a dark brown solid mass. MS:389.33[M+1]
[0192] Step-4: Synthesis of 2-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)acetonitrile [ka] To a stirred solution of 2-(1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)acetonitrile (0.040 g, 0.102 mmol) in THF (3.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.003 g, 0.0205 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography using 3%-5% MeOH in DCM as eluent to give 2-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)acetonitrile (0.008 g, 19.5%) as an off-white solid. MS:400.33[M+1]
[0193] Synthesis of compound No. 1150: 4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-N-cyclopropyl-5,5,5-trifluoropentanamide [ka]
[0194] Step-1: Synthesis of 4-(6-bromopyridin-3-yl)-5,5,5-trifluoropentanenitrile [ka] To a stirred solution of 2-bromo-5-(4-bromo-1,1,1-trifluorobutan-2-yl)pyridine (2.0 g, 5.797 mmol) in DMSO (10 mL) and water (2 mL) was added potassium cyanide (0.75 g, 11.594 mmol) at room temperature under nitrogen and heated at 80 °C overnight. The reaction progress was monitored by TLC. After completion, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 15% acetone in hexane as eluent to give 4-(6-bromopyridin-3-yl)-5,5,5-trifluoropentanenitrile (1.1 g, 65.08%) as a dark brown sticky mass. MS:293.08[M+1]
[0195] Step-2: Synthesis of 4-(6-bromopyridin-3-yl)-5,5,5-trifluoropentanoic acid [ka] Concentrated HCl (10 mL) was added to 4-(6-bromopyridin-3-yl)-5,5,5-trifluoropentanenitrile (1.0 g, 3.412 mmol) in a sealed tube and heated to 80° C. for 5 h. Reaction progress was monitored by TLC. After completion, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure to give 4-(6-bromopyridin-3-yl)-5,5,5-trifluoropentanoic acid (0.6 g, 56.6%) as a dark brown sticky mass. MS:312.08[M+1]
[0196] Step-3: Synthesis of 4-(6-bromopyridin-3-yl)-N-cyclopropyl-5,5,5-trifluoropentanamide [ka] To a stirred solution of 4-(6-bromopyridin-3-yl)-5,5,5-trifluoropentanoic acid (0.15 g, 0.4823 mmol) and cyclopropylamine (0.033 g, 0.5787 mmol) in DMF (5 mL) was added EDCI (0.110 g, 0.5787 mmol), HOBT (0.097 g, 0.723 mmol) and NMM (0.146 g, 1.446 mmol) at 10° C. The resulting reaction mixture was stirred at room temperature for 16 hours. The reaction was monitored by TLC. Upon completion, the reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude product 4-(6-bromopyridin-3-yl)-N-cyclopropyl-5,5,5-trifluoropentanamide (0.150 g, 88.8%) as a yellow oil. MS:351.16[M+1]
[0197] Step-4: Synthesis of 4-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-N-cyclopropyl-5,5,5-trifluoropentanamide [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.06 g, 0.292 mmol) and compound 4-(6-bromopyridin-3-yl)-N-cyclopropyl-5,5,5-trifluoropentanamide (0.150 g, 0.536 mmol) in dioxane (5 ml) was added K3PO4 (0.124 g, 0.585 mmol), followed by CuI (0.011 g, 0.0585 mmol) and DMEDA (0.128 g, 1.463 mmol). The reaction was heated at 110° C. for 6 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography using 2% MeOH in DCM as eluent to give 4-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-N-cyclopropyl-5,5,5-trifluoropentanamide (0.05 g, 35.9%) as a yellow solid. MS:476.42[M+1]
[0198] Step-5: Synthesis of 4-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-N-cyclopropyl-5,5,5-trifluoropentanamide [ka] To a stirred solution of 4-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-N-cyclopropyl-5,5,5-trifluoropentanamide (0.050 g, 0.105 mmol) in EtOH (10 mL) was added NH4Cl (2.5 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.029 g, 0.526 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with H2O:EtOAc (50 mL, 5:5) and filtered through Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give pure 4-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-N-cyclopropyl-5,5,5-trifluoropentanamide (0.040 g, 85.4%) as a dark brown solid mass. MS:446.44[M+1]
[0199] Step-6: Synthesis of 4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-N-cyclopropyl-5,5,5-trifluoropentanamide [ka] To a stirred solution of 4-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-N-cyclopropyl-5,5,5-trifluoropentanamide (0.040 g, 0.0898 mmol) in THF (3.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.003 g, 0.0179 mmol) and stirred at 70° C. for 4 hours. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography using 3%-5% MeOH in DCM as eluent to give 4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-N-cyclopropyl-5,5,5-trifluoropentanamide (0.020 g, 49.0%) as an off-white solid. MS:456.44[M+1]
[0200] Synthesis of compound No. 1131: 1-(4-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidin-1-yl)ethanone 1 [ka] Step-1: Synthesis of N-methoxy-N-methylcyclopropanecarboxamide: [ka] To a stirred solution of 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (10.0 g, 43.66 mmol) and N-methoxymethanamine hydrochloride (5.56 g, 56.76 mmol) in DMF (35 mL) was added DCC (13.51 g, 65.49 mmol) and DMAP (1.60 g, 13.98 mmol) sequentially at 0° C. and allowed to stir for 30 min. The resulting reaction mass was allowed to warm to room temperature and stirred for 4 h. The reaction completion was monitored by TLC. Upon completion, the reaction mixture was quenched with 1N aqueous HCl and extracted with EtOAc. The organic layer was washed with aqueous bicarbonate, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 20% acetone in n-hexane to give tert-butyl 4-(N-methoxy-N-methylcarbamoyl)piperidine-1-carboxylate (7.45 g, 60%) as a colorless oily mass. MS:273.1[M+1]
[0201] Step-2: Synthesis of tert-butyl 4-(6-bromonicotinoyl)piperidine-1-carboxylate: [ka] To a stirred solution of 2,5-dibromopyridine (5.0 g, 21.18 mmol) in diethyl ether (100 mL) was added n-butyllithium (2.5 M in hexane) (8.47 mL, 21.18 mmol) at −78° C. under nitrogen and stirred at the same temperature for 1 h. Then tert-butyl 4-(N-methoxy-N-methylcarbamoyl)piperidine-1-carboxylate (6.36 g, 23.29 mmol) was added dropwise to the reaction mixture and stirred at −78° C. for 1 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with 10% MeOH in DCM. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure to give tert-butyl 4-(6-bromonicotinoyl)piperidine-1-carboxylate (5.8 g, 67.12%) as a colorless oily mass. MS:371.0[M+1]
[0202] Step-3: Synthesis of tert-butyl 4-(1-(6-bromopyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidine-1-carboxylate [ka] To a stirred solution of tert-butyl 4-(6-bromonicotinoyl)piperidine-1-carboxylate (1 g, 2.71 mmol) in DME (50 mL) was added TMSCF3 (0.77 g, 5.43 mmol) under nitrogen at 0° C., followed by portionwise addition of CsF (0.82 g, 5.43 mmol) to the reaction mixture. The reaction mixture was allowed to warm to room temperature and stirred for 10 hours. Upon completion, the reaction mixture was quenched with 0.1 N HCL and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 10% acetone in hexane as the eluent to give tert-butyl 4-(1-(6-bromopyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidine-1-carboxylate (0.52 g, 45.45%) as a white solid. MS:440[M+2]
[0203] Step-4: Synthesis of tert-butyl 4-(1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidine-1-carboxylate [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.20 g, 0.975 mmol) and compound 4-(1-(6-bromopyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidine-1-carboxylate (0.428 g, 0.975 mmol) in DMSO (6 ml) was added K2CO3 (0.403 g, 2.92 mmol), followed by CuI (0.016 g, 0.0975 mmol) and L-proline (0.056 g, 0.487 mmol). The reaction was heated at 110° C. for 16 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 40-60% acetone in n-hexane to give tert-butyl 4-(1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidine-1-carboxylate (0.075 g, 15.12%) as a yellow solid. MS:564.02[M+1]
[0204] Step-5: Synthesis of 1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(piperidin-4-yl)ethanol [ka] To a stirred solution of tert-butyl 4-(1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidine-1-carboxylate (0.075 g, 13.51 mmol) in DCM (50 mL) was added TFA (0.2 g, 13.51 mmol) dropwise at room temperature under nitrogen. The reaction mixture was allowed to warm to room temperature and stirred for 6 hours. Upon completion, the reaction mixture was quenched with bicarbonate solution and extracted with 10% MeOH in DCM. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 4-5% MeOH in DCM as the eluent to give (6-bromopyridin-3-yl)(piperidin-4-yl)methanone (43 g, 74.52%) as a yellow solid. MS:364.16[M+1]
[0205] Step-6: Synthesis of 1-(4-(1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidin-1-yl)ethanone [ka] To a stirred solution of (6-bromopyridin-3-yl)(piperidin-4-yl)methanone 1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(piperidin-4-yl)ethanol (0.040 g, 0.109 mmol) in dry DCM (5 mL) was added Et3N (0.033 g, 0.329 mmol) under nitrogen at 0° C. To the resulting reaction mixture, acetyl chloride (0.005 g, 0.109 mmol) was added dropwise to the reaction mixture and stirred at 0° C. for 1 hour. Warmed to room temperature and stirred for 1 hour. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified on silica gel (100-200 mesh) on a flash column chromatography using 2-3% MeOH in DCM as eluent to give 1-(4-(1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidin-1-yl)ethanone (0.035 g, 63.63%) as a yellow solid. MS:506.01[M+1]
[0206] Step-7: Synthesis of 1-(4-(1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidin-1-yl)ethenone [ka] To a stirred solution of 1-(4-(1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidin-1-yl)ethanone (0.035 g, 0.0693 mmol) in EtOH (3.0 mL) was added NH4Cl (2.5 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.019 g, 0.346 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with HO:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give 1-(4-(1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidin-1-yl)ethanone (0.025 g, 78.12%) as a dark brown solid mass. MS:476.19[M+1] Step-8: Synthesis of 1-(4-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidin-1-yl)ethenone [ka] To a stirred solution of 1-(4-(1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidin-1-yl)ethanone (0.025 g, 0.05263 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.003 g, 0.0052 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (100-200 mesh) using 5-6% MeOH in DCM as the eluent to give 1-(4-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidin-1-yl)ethanone (0.006 g, 17.41%) as an off-white solid. MS:486.02[M+1]
[0207] Synthesis of compound No. 1133: 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylpiperidin-4-yl)ethanol [ka] Step-1: Synthesis of 1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylpiperidin-4-yl)ethanol [ka] To a stirred solution of 1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(piperidin-4-yl)ethanol (0.110 g, 0.023 mmol) in dry methanol (5 mL) was added formic acid (0.030 g, 0.071 mmol) and formaldehyde (0.021 g, 0.071 mmol) at room temperature under nitrogen. The reaction mixture was stirred at 70° C. for 6 hours. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (100-200 mesh) using 5-6% MeOH in DCM as the eluent to give 1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylpiperidin-4-yl)ethanol (0.060 g, 53.63%) as a yellow solid. MS:478.01[M+1]
[0208] Step-2: 1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylpiperidin-4-yl)ethanol [ka] To a stirred solution of 1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylpiperidin-4-yl)ethanol (0.060 g, 0.0125 mmol) in EtOH (7.0 mL) was added NH4Cl (2.5 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.033 g, 0.062 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with H2O:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give 1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylpiperidin-4-yl)ethanol (0.040 g, 71.4%) as a dark brown solid mass. MS:448.19[M+1]
[0209] Step-3: Synthesis of 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylpiperidin-4-yl)ethanol [ka] To a stirred solution of 1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylpiperidin-4-yl)ethanol 0.040 g, 0.0089 mmol) in THF (1.0 mL) was added trimethyl orthoformate (2.0 mL). To the resulting reaction mixture was added PTSA (0.003 g, 0.0052 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (100-200 mesh) using 5-6% MeOH in DCM as the eluent to give 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylpiperidin-4-yl)ethanol (0.014 g, 34.41%) as an off-white solid. MS:458.02[M+1]
[0210] Compound No. 1146: Synthesis of N-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)methanesulfonamide [ka] Step-1: Synthesis of 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethanone: [ka] To a stirred solution of 2,5-dibromopyridine (5.0 g, 2.12 mmol) in THF (50 mL) was added n-butyllithium (2.5 M in hexane) (12.5 mL, 3.18 mmol) under nitrogen at −78° C. and stirred at the same temperature for 1 h. Then 2,2,2-trifluoro-1-morpholinoethanone (5.06 g, 2.76 mmol) was added dropwise to the reaction mixture and stirred at −78° C. for 1 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with diethyl ether. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 18% ethyl acetate in hexane as the eluent to give 1-(6-bromopyridin-2-yl)-2,2,2-trifluoroethanone (3.5 g, 64.81%) as a colorless oil.
[0211] Step-2: Synthesis of (E / Z)-ethyl 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobut-2-enoate [ka] To a stirred solution of triethylphosphonoacetate (3.9 g, 1.77 mmol) and THF (60 ml) under N2 at 0° C. was added base potassium tert-butoxide (1.98 g, 1.77 mmol) in lots. The resulting mixture was stirred at room temperature for 1 h for anion generation. A solution of 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethanone (3.0 g, 1.18 mmol) in THF (15 ml) was added slowly. After addition, the mixture was stirred at room temperature for 6 h. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 9-15% EA / hexane to give (E / Z)-ethyl 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobut-2-enoate (1.5 g, 40%) as a yellow oil. MS:324[M+1]
[0212] Step-3: Synthesis of 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutan-1-ol: [ka] To a stirred solution of (E / Z)-ethyl 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobut-2-enoate (1.5 g, 462 mmol) in EtOH (30 mL) was added NaBH4 (0.520 g, 1380 mmol) at 0°C. The reaction was allowed to stir at room temperature for 14 h. The reaction was monitored by TLC. Upon completion, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with water, dried over Na2SO4 and evaporated under reduced pressure to give the crude reaction mass. Purification of the crude product was carried out via silica gel (100-200 mesh) column chromatography and the desired compound was eluted with 30% ethyl acetate / n-hexane to give 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutan-1-ol (0.610 g, 46.5%) as a clear oil. MS:284[M+1]
[0213] Step-4: Synthesis of 2-(3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutyl)isoindoline-1,3-dione [ka] To an ice-cooled stirred solution of isoindoline-1,3-dione (0.774 g, 5.28 mmol) and compounds 3-(6-bromopyridin-2-yl)-4,4,4-trifluorobutan-1-ol (1 g, 3.53 mmol) and TPP (1.3 g, 5.28 mmol) in THF (10 ml) was added DEAD (0.919 g, 5.28 mmol). The reaction was stirred at room temperature for 16 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 20% acetone in hexane to give 2-(3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutyl)isoindoline-1,3-dione (0.600 g, 42%) as a yellowish colored free-flowing solid. MS:409.1[M+1]
[0214] Step-5: Synthesis of 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutan-1-amine [ka] To a stirred solution of 2-(3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutyl)isoindoline-1,3-dione (0.500 g, 0.29 mmol) in MeOH (10 mL) was added hydrazine hydrate (3 ml) dropwise at 0° C. The resulting reaction mixture was stirred at room temperature for 4 h. The reaction completion was monitored by TLC. After completion, the reaction mass was quenched with 1N NaOH solution. The phases were separated and the aqueous layer was extracted with DCM. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutan-1-amine (0.200 g, 47.05%) was obtained as a reddish semi-solid, which was used directly in the next step. MS:284.09[M+1]
[0215] Step-6: Synthesis of: [ka] To an ice-cooled stirred solution of 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutan-1-amine (0.080 g, 0.282 mmol) in DCM (4.0 mL) was added trimethylamine (0.057 ml, 0.424 mmol) followed by MsCl (0.035 g, 0.252 mmol). The resulting reaction mixture was added and stirred at room temperature for 3 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with dichloromethane. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 10-15% acetone / hexane to give (0.070 g, 81.20%) as a reddish semi-solid. MS:363[M+2]
[0216] Step-7: Synthesis of N-(3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)methanesulfonamide [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.040 g, 0.195 mmol) and compound N-(3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutyl)methanesulfonamide (0.070 g, 0.195 mmol) in dioxane (5 ml) was added K3PO4 (0.080 g, 0.585 mmol), followed by CuI (0.005 g, 0.0195 mmol) and DMEDA (0.017 g, 0.195 mmol). The reaction was heated at 110° C. for 6 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 6-7% MeOH in DCM to give N-(3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)methanesulfonamide (0.035 g, 50%) as a yellow solid. MS:466.1[M+1]
[0217] Step-8: Synthesis of N-(3-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)methanesulfonamide [ka] To a stirred solution of N-(3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)methanesulfonamide (0.035 g, 0.11 mmol) in EtOH (7.0 mL) was added NH4Cl (2.0 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.029 g, 0.55 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with HO:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give pure N-(3-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)methanesulfonamide (0.025 g, 75%) as a dark brown solid mass. MS:456.2[M+1]
[0218] Step-9: Synthesis of N-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)methanesulfonamide: [ka] To a stirred solution of N-(3-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)methanesulfonamide (0.025 g, 0.079 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.0027 g, 0.015 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and 10% MeO in DCM. H. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent: 8-9% MeOH in DCM to give N-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)methanesulfonamide (0.006 g, 60%) as an off-white solid. MS:466.45[M+1]
[0219] Synthesis of compound No. 1152: 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutan-1-amine [ka] Step-1: Synthesis of 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethanone [ka] To a stirred solution of 2,5-dibromopyridine (5.0 g, 2.12 mmol) in THF (50 mL) was added n-butyllithium (2.5 M in hexane) (12.5 mL, 3.18 mmol) under nitrogen at −78° C. and stirred at the same temperature for 1 h. Then 2,2,2-trifluoro-1-morpholinoethanone (5.06 g, 2.76 mmol) was added dropwise to the reaction mixture and stirred at −78° C. for 1 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with diethyl ether. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 18% ethyl acetate in hexane as the eluent to give 1-(6-bromopyridin-2-yl)-2,2,2-trifluoroethanone (3.5 g, 64.81%) as a colorless oil.
[0220] Step-2: Synthesis of (E / Z)-ethyl 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobut-2-enoate [ka] To a stirred solution of triethylphosphonoacetate (3.9 g, 1.77 mmol) and THF (60 ml) under N2 at 0° C. was added base potassium tert-butoxide (1.98 g, 1.77 mmol) in lots. The resulting mixture was stirred at room temperature for 1 h for anion generation. A solution of 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethanone (3.0 g, 1.18 mmol) in THF (15 ml) was added slowly. After addition, the mixture was stirred at room temperature for 6 h. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 9-15% EA / hexane to give (E / Z)-ethyl 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobut-2-enoate (1.5 g, 40%) as a yellow oil. MS:254[M+2]
[0221] Step-3: Synthesis of 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutan-1-ol: [ka] To a stirred solution of (E / Z)-ethyl 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobut-2-enoate (1.5 g, 462 mmol) in EtOH (30 mL) was added NaBH4 (0.520 g, 1380 mmol) at 0°C. The reaction was allowed to stir at room temperature for 14 h. The reaction was monitored by TLC. Upon completion, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with water, dried over Na2SO4 and evaporated under reduced pressure to give the crude reaction mass. Purification of the crude product was carried out via silica gel (100-200 mesh) column chromatography and the desired compound was eluted with 30% ethyl acetate / n-hexane to give 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutan-1-ol (0.610 g, 46.5%) as a clear oil. MS:284[M+1]
[0222] Step-4: Synthesis of 2-bromo-5-(4-bromo-1,1,1-trifluorobutan-2-yl)pyridine [ka] To a stirred solution of 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutan-1-ol (0.500 g, 1.76 mmol) in DCM (20 mL) was added TPP (0.922 g, 3.52 mmol) followed by portionwise addition of carbon tetrabromide (1.16 g, 3.521 mmol) at 0° C. The resulting reaction mixture was stirred at room temperature for 7 hours. The completion of the reaction was monitored by TLC. After completion, the reaction mass was quenched with ice-cold water. The phases were separated and the aqueous layer was extracted with DCM. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 5-7% acetone in hexane as the eluent to give 2-bromo-5-(4-bromo-1,1,1-trifluorobutan-2-yl)pyridine (0.300 g, 47.05%) as a reddish colored semi-solid. MS:346.97[M+1]
[0223] Step-5: Synthesis of tert-butyl 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutylmethylcarbamate [ka] To a stirred solution of 2-bromo-5-(4-bromo-1,1,1-trifluorobutan-2-yl)pyridine (0.300 g, 0.867 mmol) in THF (10 mL) was added methylamine in THF (3 ml) followed by Et3N (0.262 g, 2.60 mmol) at 0° C. The resulting reaction mixture was stirred at room temperature for 4 hours. The completion of the reaction was monitored by TLC. After completion, the reaction mass was quenched with water. The phases were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The obtained 3-(6-bromopyridin-3-yl)-4,4,4-trifluoro-N-methylbutan-1-amine (93.75%), (0.240 g, 0.8080 mmol) was dissolved in DCM (10 mL) and Boc anhydride (0.264 g, 1.21 mmol) was added followed by Et3N (0.204 g, 2.02 mmol) at 0° C. The resulting reaction mixture was stirred at room temperature for 6 hours. The completion of the reaction was monitored by TLC. After completion, the reaction mass was quenched with water. The phases were separated and the aqueous layer was extracted with DCM. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. tert-Butyl 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutylmethylcarbamate (0.200 g, 49.05%) was obtained as an off-white solid which was used directly in the next step. MS:397.09[M+1]
[0224] Step-6: Synthesis of tert-butyl 3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutylmethylcarbamate [ka] To a stirred solution of 3-nitro-4-(1H-pyrazol-4-yl)pyridin-2-amine (0.100 g, 0.487 mmol) and compound tert-butyl 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutylmethylcarbamate (0.193 g, 0.48 mmol) in dioxane (5 ml) was added K3PO4 (0.305 g, 1.44 mmol), followed by CuI (0.009 g, 0.048 mmol) and DMEDA (0.042 g, 0.48 mmol). The reaction was heated at 110° C. for 6 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 3-5% MeOH in DCM to give tert-butyl 3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutylmethylcarbamate (0.070 g, 50%) as a yellow solid. MS:522.1[M+1]
[0225] Step-7: Synthesis of tert-butyl 3-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutylmethylcarbamate: [ka] To a stirred solution of tert-butyl 3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutylmethylcarbamate (0.052 g, 1.91 mmol) in EtOH (7.0 mL) was added NH4Cl (2.0 mL) at room temperature. To the resulting reaction mixture, Fe powder (0.52 g, 9.51 mmol) was added and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, the reaction mixture was diluted with H2O:EtOAc (50 mL, 5:5) and passed over Celite to remove inorganic impurities from the reaction mixture. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give pure tert-butyl 3-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutylmethylcarbamate (0.036 g, 75%) as a dark brown solid mass. MS:492.2[M+1]
[0226] Step-8: Synthesis of tert-butyl 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutylmethylcarbamate: [ka] To a stirred solution of tert-butyl 3-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutylmethylcarbamate (0.035 g, 0.079 mmol) in THF (1.0 mL) was added trimethyl orthoformate (1.5 mL). To the resulting reaction mixture was added PTSA (0.0027 g, 0.015 mmol) and stirred at 70° C. for 4 h. The reaction was monitored for completion by TLC. Upon completion, it was quenched with aqueous bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude desired product, which was purified by silica gel (100-200 mesh) column chromatography: eluent with 8-9% MeOH in DCM to give tert-butyl 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutylmethylcarbamate (0.021 g, 60%) as an off-white solid. MS:502.1[M+1]
[0227] Step-9: Synthesis of 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutan-1-amine: [ka] To a stirred solution of tert-butyl 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutylmethylcarbamate (0.021 g, 0.0419 mmol) in DCM (50 mL) was added TFA (0.004 g, 0.0419 mmol) dropwise at room temperature under nitrogen. The reaction mixture was allowed to warm to room temperature and stirred for 6 h. Upon completion, the reaction mixture was quenched with bicarbonate solution and extracted with 10% MeOH in DCM. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using 4-5% MeOH in DCM as the eluent to give 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutan-1-amine (0.05 g, 31.25%) as an off-white solid. MS:402.1[M+1]
[0228] Compounds of the invention were tested for these activities and found to be active, the assays and results being presented hereinafter.
[0229] Biological Example 1 JAK biochemical assays. Biochemical assays were developed using recombinant JAK1, JAK2, JAK3 and TYK2 (Carna Biosciences) in 50 mM HEPES pH 7.5, 1 mM EGTA, 10 mM MgCl2, 2 mM DTT and 0.01% Tween-20. The amount of enzyme, substrate (ULigh-JAK-1(Tyr1023) peptide) and ATP concentration used for each kinase assay were determined by respective titration and Km experiments. Biochemical assays were developed with LANCE Ultra TR-FRET technology (Perkin Elmer). Enzymes and compounds were incubated for 60 min at 22° C. in white 384-well optiplates (Perkin Elmer). Substrate and ATP were added to the mix and incubated for another 90 min. The reaction was terminated by adding EDTA and detection antibody (Europium-anti-phospho-tyrosine (PT66) antibody). The assays were read on a BMG FLUOstar multimode reader in TR-FRET mode. Upon irradiation at 320 nm, energy from the Eu donor is transferred to the ULight acceptor dye, which in turn generates light at 665 nm. The intensity of the light emission is proportional to the level of ULight substrate phosphorylation. Compounds that interfere with JAK enzyme activity show lower substrate phosphorylation and predict values in terms of % inhibition compared to vehicle control.
[0230] Biological Example 2 Assay of JAK cells-STAT3 and STAT5 phosphorylation by IL-6 and GMCSF TF-1 cells were starved overnight in OptiMEM medium containing 0.5% charcoal stripped fetal bovine serum, 0.1 mM non-essential amino acids (NEAA), 1 mM sodium pyruvate, and phenol red-free in a CO2 incubator maintained at 37°C. The next day, cells were resuspended in RPMI without phenol red and dispensed into 96-well plates at a final cell density of 1,20,000 cells per well. Compounds were diluted in DMSO, added to cells, and incubated for 30 minutes in a CO2 incubator maintained at 37°C. The final DMSO concentration in the cell-based assay was 0.2%. Human recombinant cytokines, IL-6 (30 ng / ml) and GMCSF (5 ng / ml), were added to the plate containing cells along with compounds and incubated for 20 minutes with gentle tapping once every 5 minutes. Compound-mediated effects on STAT3 and STAT5 phosphorylation were measured in prepared lysates using CISBIO pSTAT3 and pSTAT5 detection kits by HTRF method.The background signal obtained from cells not activated by cytokines was subtracted from vehicle control and compound-treated wells.The inhibition percentage of pSTAT3 / 5 levels by compounds was calculated from vehicle control, which was taken as 100% pSTAT3 / 5 control.
[0231] Biological Example 3 STAT5 phosphorylation by IL-2 HT-2 cells were starved overnight in RPMI phenol red with 10% fetal bovine serum in a CO2 incubator maintained at 37°C for 4 hours. Compounds were diluted in DMSO and added to 96-well plates containing cells at a final density of 1,20,000 cells per well. Cells and compounds were incubated for 30 minutes in a CO2 incubator maintained at 37°C, with a final DMSO concentration of 0.2% in the cell-based assay. Human recombinant cytokine, IL-2 (50U / ml), was added to the plate containing cells and compounds and incubated for 20 minutes with gentle tapping / shaking once every 5 minutes. Compound-mediated effects on STAT5 phosphorylation were measured in prepared lysates by HTRF method using the CISBIO pSTAT5 detection kit. Background signals from cells not activated by cytokines were subtracted from vehicle control and compound-treated wells. The percentage of inhibition of pSTAT5 levels by compounds was calculated from the vehicle control, which was taken as the 100% pSTAT5 control.
[0232] Biological Example 4 IL-12-induced IFN-γ production in NK92 cells NK92 cells were cultured overnight in medium without IL-2. The next day, NK92 cells were seeded in 96-well plates at 5000 cells per well. Compounds were added to the cells and incubated for 1 hour. IL-12, 10U / ml, was then added to the cells and incubated overnight. Supernatants were collected from the wells and IFN-γ secretion was measured using a human IFN-γ ELISA kit. Absorbance was measured at 450 nm on a BMG FLUOstar. Background signals from cells not activated by cytokines were subtracted from vehicle control and compound-treated wells. Percentage inhibition of IFN-γ secretion by compounds was calculated from vehicle control, which was taken as 100% IFN-γ secretion.
[0233] Compounds of the present invention were tested as in Biological Examples 1-4, with the results in Table 2 below. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8] [Table 2-9]
[0234] From Table 2 it can be clearly seen that all the compounds of the present invention possess activity as selective JAK1 inhibitors.
[0235] Biological Example 5 Comparison with existing JAK inhibitors As an example, certain exemplary compounds were tested for their activity in comparison with existing JAK inhibitors. Examples 1133, 1181 and 1215 were compared with the results of existing JAK inhibitors under the same experimental conditions, and the results are shown in Table 3.
[0236] [Table 3]
[0237] The data thus generated for the compounds were compared with two reference standards, filgotinib-JAK1 selective inhibitor, and tofacitinib-panJAK inhibitor. Examples 1133, 1181 and 1215 showed better potency and selectivity for JAK1 (7-80 fold selectivity for JAK1 vs. JAK2; 3-22 fold selectivity for JAK1 vs. JAK3) compared with filgotinib (0.9 fold selectivity for JAK1 vs. JAK2; 12 fold selectivity for JAK1 vs. JAK3). These compounds were also far superior in terms of JAK1 selectivity compared with pan inhibitors, such as tofacitinib.
[0238] Biological Example 6 Mouse Models of Rheumatoid Arthritis: Rheumatoid arthritis (RA) is an autoimmune disease that can cause systemic joint pain and damage. Some cytokines, such as IL-6 and IFN-γ, activate the Janus kinase / signal transducer and activator of transcription (JAK / STAT) pathway. Inhibition of the JAK / STAT pathway is considered as one of the therapeutic options for the treatment of rheumatoid arthritis. Arthritic rodent models can be used to evaluate the therapeutic potential of compounds administered prophylactically or therapeutically. These models include, but are not limited to, collagen-induced arthritis in mice or rats, rat adjuvant-induced arthritis, and collagen antibody-induced arthritis.
[0239] The compounds described herein are tested for efficacy induced by JAK / STAT pathway inhibition in collagen-induced mouse arthritis model.Compounds are orally dosed QD for 21 days, and at the end of the experiment, clinical symptoms, body weight and ankle and foot histopathology are measured.Arthritis scores are calculated for compounds and reference standard, filgotinib.Illustratively, examples 1215, 1181 and 1133 show very good efficacy, which is better or equal to filgotinib.
[0240] Biological Example 7 Mouse model of imiquimod-induced psoriasis: Imiquimod (IMQ)-induced dermatitis closely resembles human psoriatic lesions not only in terms of phenotype and histological features, but also in the development of lesions. IMQ is a ligand for Toll-like receptor 7 (TLR7) and TLR8, and is a potent immunoactivator. The immunomodulatory effect of IMQ in causing psoriasis is due to the stimulation of TLR7 and TLR8 on plasmacytoid dendritic cells (pDCs) and upregulated type I interferon pathway. The migration of activated dermal dendritic cells in the skin to lymph nodes triggers a series of events that lead to the late phase of psoriasis. The compounds described herein were tested for efficacy induced by JAK inhibition in imiquimod-induced dermatitis in mice.
[0241] Female BALB / c mice were topically dosed with a 3% cream formulation containing the test compound. Four hours after administration of the test compound, 5% imiquimod was applied to the back skin and right ear for 5 days. On the sixth day, after administration of the test compound, the severity of psoriasis was monitored and scored according to the Psoriasis Area and Severity Index (PASI). The efficacy of the compound was evaluated based on the PASI score. Redness, thickness, and scaling of the back skin and ear were evaluated in the scoring group.
[0242] The compounds of the present invention, such as Example 1133, Example 1215 and filgotinib, showed statistically significant reduction in cumulative psoriasis score compared to vehicle. There was a significant reduction in back skin thickness, ear thickness for administration of Example 1133, 1215 and filgotinib (3% topical, QD). Example 1215 showed better efficacy compared to 1133 and reference compound filgotinib. The data is represented in the format of Figure 1. It can be clearly seen from the figure that exemplary compounds of the present invention show enhanced efficacy compared to commercial compounds such as filgotinib.
[0243] Biological Example 9 Murine model of oxazolone-induced colitis: The animal in which colitis occurs can be any mammal, including but not limited to mouse, rat, guinea pig, hamster, rabbit, cat, dog, goat, monkey, and chimpanzee.Colitis can be caused in animals by any method known in the art.A mouse model of oxazolone-induced colitis was used to study the effectiveness of JAK inhibitors.Oxazolone colitis has histological similarities with human ulcerative colitis.Proinflammatory cytokines that are elevated in ulcerative colitis depend on the JAK family of tyrosine kinases for signal transduction.It has been proposed that JAK inhibition can be beneficial in the treatment of ulcerative colitis.
[0244] Male BALB / c mice aged 10–12 weeks were used in the experiments. On day 1, 4% oxazolone (in a 4:1 acetone:olive oil formulation) or vehicle solution was applied between the shoulders of anesthetized animals. Seven days after skin sensitization, mice were fasted for 6 h before intrarectal administration of 1% oxazolone (in a 1:1 ethanol:water formulation). Drug treatment or vehicle administration (PO, BID) began on day 6, the day before intrarectal oxazolone administration. Animals were dosed with test compound or vehicle until day 9. A treatment-blinded experimenter scored each mouse for a disease activity index (DAI). Weight loss (0=none, 2=>5–10%, 4=>20%), stool consistency (0=normal, 2=soft, no globular stools, 4=severe diarrhea) and rectal bleeding (0=no blood, 2=blood in stool, 4=blood on anus and part of tail) were assessed with a DAI score.
[0245] Table 4 below sets forth the scores of compounds on the Disease Activity Index parameters in comparison to the vehicle treated group.
[0246] [Table 4]
[0247] The compounds of the present invention, such as Example 1181, 1215 and filgotinib, showed statistically significant reduction in disease activity index compared with vehicle.For the administration of Example 1181, 1215 and filgotinib (30mpk, PO, BID), there was a significant reduction in stool consistency, rectal bleeding and weight loss parameters.Example 1215 showed better efficacy compared with the marketed compound filgotinib.
Claims
1. 1064. N-(2,2,2-trifluoroethyl)-4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1066. N-(2-cyanocyclohexyl)-4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1075. 2-(2-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)oxazol-4-yl)acetonitrile; 1076. 2-(2-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)thiazol-4-yl)acetonitrile; 1078. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)acetonitrile; 1080. 7-(1-(5-((methylsulfonyl)methyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1081. 7-(1-(5-((oxetan-3-yl)methyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1082. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)acetonitrile hydrochloride; 1083. (6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)methanol; 1084. 7-(1-(5-(2,2,2-trifluoroethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1085. 7-(1-(5-(morpholinomethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1086. 4-((6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)methyl)thiomorpholine 1,1-dioxide; 1087. 1-((6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)methyl)azetidine-3-carbonitrile; 1088. 6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)-N-(cyanomethyl)pyridine-3-carboxamide; 1089. N-((6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)methyl)methanesulfonamide; 1090. N-((6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)methyl)methanesulfonamide; 1091. N-((6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)methyl)-2-cyanoacetamide; 1092. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-N-(2,2,2-trifluoroethyl)acetamide; 1093. 2-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)-N-(cyanomethyl)pyrimidine-5-carboxamide; 1094. N-(2,2,2-trifluoroethyl)-4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carboxamide; 1095. 4-(2-ethoxy-3H-imidazo[4,5-b]pyridin-7-yl)-N-(2,2,2-trifluoroethyl)-1H-pyrazole-1-carboxamide; 1098. 4-(2-(1-acetylpiperidin-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)-N-(2,2,2-trifluoroethyl)-1H-pyrazole-1-carboxamide; 1099. 2-(4-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)phenyl)acetonitrile; 1100. 2-(4-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)phenyl)-2-cyclopropylacetonitrile; 1101. 2-(4-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)phenyl)-2-morpholinoacetonitrile; 1102. N-(4-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)phenyl)-2-cyanoacetamide; 1103. 2-(4-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)-3-fluorophenyl)acetonitrile; 1106. 2-(3-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)phenyl)acetonitrile; 1107. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)propanenitrile; 1108. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)propenamide; 1109. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)cyclopropanecarbonitrile; 1110. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-cyclopropylacetonitrile; 1111. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(3,3-difluoroazetidin-1-yl)acetonitrile; 1112. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-morpholinoacetonitrile; 1113. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(1,1-dioxidethiomorpholino)acetonitrile; 1114. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(1-(methylsulfonyl)azetidin-3-yl)acetonitrile; 1115. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(1-(methylsulfonyl)azetidin-3-yl)acetonitrile; 1116. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4-(methylsulfonyl)butanenitrile; 1118. 2-(2-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-4-yl)acetonitrile; 1119. 7-(1-(5-(2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1120. 7-(1-(5-(1-chloro-2,2,2-trifluoroethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1121. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-N,N-dimethylethanamine; 1122. 7-(1-(5-(1,1,1-trifluorobutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1123. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutanenitrile; 1125. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1,1,1-trifluoropropan-2-ol; 1126. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-cyclopropyl-2,2,2-trifluoroethanol; 1127. 7-(1-(5-(1-cyclopropyl-2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1128. 7-(1-(5-(1,1,1,2-tetrafluoropropan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1129. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1,1,1-trifluoro-3-methylbutan-2-ol; 1130. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-cyclohexyl-2,2,2-trifluoroethanol; 1131. 1-(4-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidin-1-yl)ethenone; 1132. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-cyclopentyl-2,2,2-trifluoroethanol; 1133. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylpiperidin-4-yl)ethanol; 1134. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(tetrahydro-2H-pyran-4-yl)ethanol; 1135. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(piperidin-4-yl)ethan-1-ol; 1136. 7-(1-(5-(2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1137. 7-(1-(5-(2,2,2-trifluoro-1-morpholinoethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1138. 7-(1-(5-(1,1,1-trifluoro-3-(methylsulfonyl)propan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1139. 7-(1-(5-(4-(cyclopropylsulfonyl)-1,1,1-trifluorobutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1140. 7-(1-(5-(1-((methylsulfonyl)methoxy)-2,2,2-trifluoroethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1141. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutane-1-sulfonamide; 1142. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutane-1-sulfonamide; 1143. N-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)methanesulfonamide; 1144. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N,N-dimethylbutanamide; 1145. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutanamide; 1146. 1-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethyl)-3-cyclopropylurea; 1147. 7-(1-(5-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one; 1148. 4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-5,5,5-trifluoro-N-methylpentanamide; 1149. N-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)cyclopropanecarboxamide; 1150. 4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-N-cyclopropyl-5,5,5-trifluoropentanamide; 1151. N-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)cyclopentanecarboxamide; 1152. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutan-1-amine; 1153. N-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)cyclopropanamine; 1154. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutan-1-ol; 1155. 7-(1-(5-(1,1,1-trifluoro-4-methoxybutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1156. 4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-5,5,5-trifluoropentanenitrile; 1157. 2-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)acetonitrile; 1158. 7-(1-(5-(1-(methylsulfonyl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1159. (6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)(cyclopropyl)methanol; 1160. 7-(1-(5-(3-(methylsulfonyl)-1-(oxetan-3-yl)propyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1161. 7-(1-(5-(1-methoxy-3-(methylsulfonyl)propyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1162. 7-(1-(5-(1-fluoro-3-(methylsulfonyl)propyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1163. 7-(1-(5-(4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1164. (6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)(1-(methylsulfonyl)piperidin-4-yl)methanol; 1165. (6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)(1-methylpiperidin-4-yl)methanol; 1166. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-N-(2,2,2-trifluoroethyl)-2-hydroxyacetamide; 1167. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-cyclopropyl-N-(2,2,2-trifluoroethyl)acetamide; 1168. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-cyano-N-(2,2,2-trifluoroethyl)acetamide; 1169. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethanol; 1170. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-2-yl)-2,2,2-trifluoroethanol; 1171. 7-(1-(6-(2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1172. 1-(2-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-4-yl)-2,2,2-trifluoroethanol; 1173. 1-(5-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-2-yl)-2,2,2-trifluoroethanol; 1174. 7-(1-(5-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1175. 7-(1-(6-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1176. 7-(1-(4-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1178. 1-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethyl)-3-cyclopropylurea; 1179. 1-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)-3-cyclopropylurea; 1180. 3-Cyclopentyl-3-(4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)propanenitrile; 1181. 7-(1-(5-((S)-1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1182. 7-(1-(5-((R)-1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1183. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1,1,1-trifluoropropan-2-ol; 1184. 7-(1-(5-((R)-2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1186. 7-(1-(5-(1,1,1-trifluoro-4-(isopropylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1187. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-(methylsulfonyl)1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethanamine; 1188. 7-(1-(5-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-(cyclopropylaminosulfonyl)1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1189. 7-(1-(5-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one; 1190. 7-(1-(4-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)phenyl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1191. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(trifluoromethyl)propan-1-ol; 1192. N-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethyl)-2-cyanoacetamide; 1193. 4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-5,5,5-trifluoro-2-methylpentan-2-ol; 1194. 7-(1-(5-(3,3,3-trifluoro-2-((methylsulfonyl)methyl)propyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1195. N-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)-N-methylcyclopropanamine; 1197. N-(2-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)ethyl)cyclopropanamine; 1198. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutan-1-amine; 1199. N-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)cyclohexanamine; 1200. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutan-1-amine; 1201. 7-(1-(5-(1,1,1-trifluoro-4-morpholinobutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1202. 1-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)azetidine-3-carbonitrile; 1203. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-isopropylbutan-1-amine; 1204. 7-(1-(5-(4-(cyclopropylmethylsulfonyl)-1,1,1-trifluorobutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1205. 7-(1-(5-(3-(cyclopropylmethylsulfonyl)-1,1,1-trifluoropropan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1206. 7-(1-(5-(1,1,1-trifluoro-3-morpholinopropan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1207. (S)-3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-isopropylbutan-1-amine; 1208. (R)-3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-isopropylbutan-1-amine; 1209. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-(methylsulfonyl)1H-pyrazol-1-yl)pyridin-3-yl)-3,3,3-trifluoropropan-1-amine; 1210. 4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-5,5,5-trifluoro-N-isopropylpentanamide; 1211. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N,N-diisopropylbutan-1-amine; 1212. N-(2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-3,3,3-trifluoropropyl)cyclopropanamine; 1213. (R)-3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutanamide; 1214. (S)-3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutanamide; 1215. (S)-4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-5,5,5-trifluoro-N-isopropylpentanamide; 1216. 7-(1-(5-((S)-4-(cyclopropylsulfonyl)-1,1,1-trifluorobutan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1217. (S)-3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutan-1-amine, TFA salt; 1218. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-3,3,3-trifluoro-N-isopropylpropan-1-amine; 1219. 7-(1-(5-(1,1,1-trifluoro-4-(4-methylpiperazin-1-yl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1220. (4-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidin-1-yl)(cyclopropyl)methanone; 1221. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-(1-ethylpiperidin-4-yl)-2,2,2-trifluoroethanol; 1222. 7-(1-(5-(1,1,1-trifluoro-3-(4-methylpiperazin-1-yl)propan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1223. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1,1,1-trifluoro-4-(methylsulfonyl)butan-2-ol; 1224. 5-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-6,6,6-trifluorohexan-2-amine, TFA salt; 1225. (R)-1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-isopropylpyrrolidin-3-yl)ethanol; 1226. (S)-1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-isopropylpyrrolidin-3-yl)ethanol; 1227. 4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-5,5,5-trifluoro-4-hydroxypentanenitrile; 1228. 2-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)-N-methylethanamine; 1229. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1,1,1-trifluoro-3-morpholinopropan-2-ol; 1230. 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1,1,1-trifluoro-4-morpholinobutan-2-ol; 1231. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylazetidin-3-yl)ethanol; 1232. (R)-1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-(1-ethylpyrrolidin-3-yl)-2,2,2-trifluoroethanol; 1233. (S)-1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-(1-ethylpyrrolidin-3-yl)-2,2,2-trifluoroethanol; 1234. (S)-1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylpyrrolidin-3-yl)ethanol; 1235. (R)-1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylpyrrolidin-3-yl)ethanol; 1236. 1-(3-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)azetidin-1-yl)ethenone; 1237. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-isopropylazetidin-3-yl)ethanol; 1238. 4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-5,5,5-trifluoro-4-hydroxy-N-isopropylpentanamide; 1239. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1-(1-ethylazetidin-3-yl)-2,2,2-trifluoroethanol; 1240. 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-isopropylpiperidin-4-yl)ethanol; 1241. N-(2-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)ethyl)propan-2-amine, TFA salt; 1242. (R)-1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-(oxetan-3-yl)pyrrolidin-3-yl)ethanol; 1243. (S)-1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-(oxetan-3-yl)pyrrolidin-3-yl)ethanol; 1244. 7-(1-(5-(2,2,2-trifluoro-1-methoxy-1-(1-methylpiperidin-4-yl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine; 1245. 3-(3-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)azetidin-1-yl)-3-oxopropanenitrile; 1246. 3-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)-N-methylazetidine-1-carboxamide; 1247. N-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)isobutyramide; 1248. N-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)-2-cyanoacetamide; 1249. 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-1-morpholinobutan-1-one; 1250. 1-(4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-5,5,5-trifluoropentanoyl)azetidine-3-carbonitrile; 1251. (S)-1-(4-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoro-1-(1-isopropylpyrrolidin-3-yl)ethanol; 1252. (R)-1-(4-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoro-1-(1-isopropylpyrrolidin-3-yl)ethanol or a pharma- ceutically acceptable salt or stereoisomer thereof.
2. 13. A pharmaceutical composition comprising a compound of claim 1, or a pharma- ceutically acceptable salt or stereoisomer thereof, and optionally a pharma- ceutically acceptable excipient.
3. 3. The pharmaceutical composition of claim 2 when administered orally, nasally, parenterally (intravenously, intramuscularly, or subcutaneously), topically, transdermally, intravaginally, intravesically, intracisternally, or rectally in the form of a solid, semi-solid, lyophilized powder, or liquid dosage form.
4. A pharmaceutical composition described in claim 2 or 3 for inhibiting JAK1.
5. Cancer (including carcinoma, sarcoma, lymphoma, leukemia, myeloma, germ cell tumors, blastoma, tumors of the central and peripheral nervous system, and other tumors including melanoma, seminoma, and Kaposi's sarcoma), AIDS, Addison's disease, adult respiratory distress syndrome, allergy, ankylosing spondylitis, amyloidosis, asthma, autoimmune hemolytic anemia, autoimmune thyroiditis, Crohn's disease, episodic lymphocytopenia with lymphocytotoxic factor, fetal erythroblastosis, 4. A pharmaceutical composition according to claim 2 or 3 for use in the treatment of eosinophilia, Goodpasture's syndrome, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome and other intestinal diseases, lupus, myasthenia gravis, myocardial or pericardial inflammation, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, scleroderma, systemic anaphylaxis, ulcerative colitis, nephritis, gout, arthritis, erythema, dermatitis, dermatomyositis, bronchitis, cholecystitis, sepsis or gastritis.
6. A pharmaceutical composition according to claim 2 or 3 for use in the treatment of glomerulonephritis, rheumatoid arthritis or osteoarthritis.
Citation Information
Patent Citations
N-substituted phenylacrylamide derivative and its preparation method and purpose
CN105837572A
Heterocycle and imidazole compounds, pharmaceutical composition comprising heterocycle and imidazole derivatives as well as preparation method and application of heterocycle and imidazole compounds
CN106146504A
Novel imidazo '4,5-b]pyridine derivatives as glycogen synthase kinase 3 inhibitors for use in the treatment of dementia and neurodegenerative diseases
JP2009510161A
CDK Modulator
JP2011526931A
Heteroaryl compounds as BTK inhibitors and their use
JP2017533897A
